Annual Meeting
The AACR’s Annual Meeting is one of the largest and most important annual gatherings of scientists engaged in cancer research worldwide. The next Annual Meeting will take place in Washington, D.C., from April 20–24, 1996. The Chairperson of the Annual Meeting is Lorraine J. Gudas of the Cornell University Medical College. Dr. Gudas and her Program Committee will invite outstanding scientists in the field to organize plenary sessions, symposia, methods workshops, controversy sessions, and meet-the-expert sunrise sessions. The Committee is currently reviewing proffered papers for scheduling in mini-symposia, poster discussion sessions, and poster sessions. The deadline for abstract submissions was December 1, 1995.

Gertrude Elion Cancer Research Award
Applications for the AACR’s 1996 Gertrude Elion Cancer Research Award, supported by an educational grant from Glaxo Wellcome Oncology, are due February 15, 1996. The one-year, $30,000 grant to a nontenured Assistant Professor supports meritorious basic, clinical, or translational research in cancer causation, prevention, or treatment. Tenured faculty in academia, government employees, and employees of private industry are not eligible for this award. Information and application forms were mailed to AACR members and those who have requested applications. Nonmembers should request information and applications from the AACR office.

New Research Fellowships Available
This year the AACR will offer two new one-year, $30,000 grants to clinical or postdoctoral fellows. A research award for a postdoctoral/clinical fellow in clinical/translational research will be sponsored by Amgen. A research award for a postdoctoral fellow in basic research will also be available. To be eligible for either fellowship, candidates must have completed the M.D., Ph.D., or other doctoral degree. Candidates must currently be a postdoctoral or clinical research fellow and must have been a fellow for at least two years but not more than five years prior to the year of the award. All AACR members will receive information and an application form by mail in the near future. Nonmembers may request information and forms from the AACR office. The deadline for applications for the new research fellowships is February 15, 1996.

Travel Grants from the Comprehensive Minority Biomedical Program of the National Cancer Institute
Funds are being provided through the Comprehensive Minority Biomedical Program of the National Cancer Institute for the travel of a limited number of minority students to the 1996 AACR Annual Meeting. Eligible scientists are young, full-time predoctoral students, postdoctoral fellows, and physicians in training who are engaged in cancer research or who have training that could lead to contributions in this field.

AACR
The American Association for Cancer Research (AACR) was founded in 1907 to bring together active investigators of the cancer problem for the presentation and discussion of new findings and to foster advances in cancer research. Today the Association has more than 10,000 members working in all of the subdisciplines of cancer research in the United States, Canada, and more than 50 other countries. Information on AACR programs and activities can be obtained from

American Association for Cancer Research
Public Ledger Building
150 South Independence Mall West
Suite 816
Philadelphia, PA 19106-3483
Phone: (215) 440-9300
Fax: (215) 440-9313

The AACR welcomes applications for membership from the readership. Scientists engaged in all areas of cancer research are eligible for membership. There are three categories of membership: active membership, open to cancer researchers working in the Americas; corresponding membership, to those working outside the Americas; and associate membership, to graduate and medical students, postdoctoral fellows, and physicians-in-training. Further information on the qualifications for each category as well as the benefits of membership can be found on the application forms at the back of this issue.

AACR Special Conferences in Cancer Research
A number of meetings are now being organized in the AACR’s new series of smaller scientific meetings. Following are the topics, dates, locations, and program committees for some of these meetings. When full details of each meeting are available, AACR members will be the first to receive complete brochures and application forms for participation in these important conferences. Nonmembers may receive this information by sending their names and addresses to Meetings Mailing List, American Association for Cancer Research, Public Ledger Building, 150 South Independence Mall West, Suite 816, Philadelphia, PA 19106-3483. Telephone: (215) 440-9300. Fax: (215) 440-9313. E-mail: acar@aol.com.

February 19–25, 1996
Cancer Susceptibility Genes and Molecular Carcinogenesis
Chairpersons:
ALLAN BALMAIN, Glasgow, Scotland
CURTIS C. HARRIS, Bethesda, MD
KENNETH OLDEN, Research Triangle Park, NC
Keystone Resort, Keystone, CO
March 1–5, 1996
Proteases and Protease Inhibitors
Chairpersons:
LYNN M. MATRISIAN, Nashville, TN
BONNIE F. SLOANE, Detroit, MI
Marriott’s Bay Point Resort, Panama City, Beach, FL
June 8–12, 1996
Inducible Genomic Responses
Chairpersons:
WILLIAM T. BECK, Memphis, TN
JOHN A. HICKMAN, Birmingham, England
RICHARD J. MORIMOTO, Evanston, IL
Skamania Lodge, Stevenson (Columbia River Gorge), WA
October 2–6, 1996
Novel Approaches in Blood and Marrow Transplantation
Second Annual Meeting of the American Society for Blood and Marrow Transplantation
Chairpersons:
O. MICHAEL COLVIN, Durham, NC
BRUCE R. BLAZAR, Minneapolis, MN
Hotel Del Coronado, San Diego, CA
Acknowledgment to Reviewers

The Editor-in-Chief, the Associate Editors, and the Editorial Advisory Board wish to acknowledge with sincere appreciation the assistance of the many reviewers who have generously contributed their time and efforts during the past year in the appraisal of manuscripts submitted to Clinical Cancer Research. These reviewers not only have been of invaluable help in assessing the merit of original articles but also, by their careful analysis and critique and their general and specific constructive recommendations, have often greatly enhanced the quality of these manuscripts. The quality of the journal can be attributed in large measure to the quality of their effort. We are sincerely grateful.

A
Gregory Adams
Peter Adamson
Jaffer Ajani
Mark Alberti
Anthony Albino
Maher Alhtar
Francis Ali-Osman
Michael C. Alley
D. Craig Allred
Paul Anderson
W. French Anderson
Michael Andreeff
Joseph Antin
Robert Arceci
Ralph Arlingshaus
Deborah Armstrong
Donald Armstrong
Bradley Arrick
G. Arroyo
Carlos Arteaga
Larry Arthaud
Michael Atkins
Andrew Averbach

W. Blanner
R. M. Blaese
Ronald Blasberg
R. Chris Bleackley
Brent Blumenstein
M. Boccia
Matthew Boente
Arthur Bogden
David Boldt
Bruce Boman
Michael Bookman
Ernest Borden
Epie Boven
Michael R. Boyd
Joseph Brennan
Murray Brennan
Dean Brenner
Thomas Brent
Garrett Brodeur
Carol Brown
H. Broxterman
N. Bruchovsky
C. D. Bucana
Joan Bull
Howard Burris
Stephen Byers
Gerald Clamon
John Clark
Robert Clarke
James Cleary
Alfred Cohen
Amos Cohen
Susan Cohn
Steven Collins
Barbara Conley
Claudio Conti
Fran Cook
Carlos Cordon-Cardo
José Costa
Marion Couch
Kenneth Cowan
Craig Cropp
Ronald Cristal
Kevin Cullen
Kenneth Culver
Steven D’Ambrosio
Peter Danenberg
D. Danielpour
Mary Danks
Zhigniew Darzynkiewicz
Nancy Davidson
Thomas Davis
Jerome De Conde
Marc Dellian
Elaine Derbyshire
Eugene De Sombre
E. de Vries
Daniel Dexter
Robert Diassio
Robert Dickson
Robert Dillman
C. Divgi
Ethan Dmitrovsky
Bruce Dolnide
James Doroshow
N. C. Dracopoli
Anatoly Dritschilo
C. Dumontet
Bo Dupont
Paul Duray
Harold Dvorak
Gail Eckhardt
H. Elhay
Janine Einspahr
W. El-Derby
Laurence Elias
Richard Elledge
Lee Ellis
A. El-Naggar
Barbara Ensminger
Barbara Ensoli
Gary Erdmann
Leonard Erickson
C. Erlichman
Elihu Estey
W. E. Evans

B
Dean Bajorin
D. Bank
D. Barnerjees
Sharyn Baker
Arthur Bank
Menashe Bar-Eli
José Baselga
Ashis Basu
Stephen B. Baylin
Scott Bearman
Jürgen Becker
Atul Bedi
Thomas Behr
J. Beijnen
William P. Bennett
Jeffrey L. Benovic
Andrew Berchuck
David Berd
Jonathan Berek
Nathan Berger
J. Berlin
Scott I. Berman
Irwin Bernstein
Steven H. Bernstein
J. Besterman
Kapil Bhatta
Michael Birrer

Paul Cairns
Mitchell Cairo
Bruce Camitta
Stephen Cannistra
Robert Capizzi
Giovanni Capranico
David Carbone
Philip Caron
Carlos Carrera
William Carson
Ephraim Casper
Melvin Center
Bruce Chaibner
Raju Chaganti
Helen Chan
Kai Chang
Sunil Chatterjee
Martin Cheever
Irwin Chen
Nai-Kong Cheung
Christopher Chitambar
Kathleen Cho
Randolph Christen
T. Chung
I. Frank Cierk

C
Thomas Fahey
Dominic Fan
Zhen Fan
David Farquhar
Hassan Fatallah-Shaykh
E. Feigal
David Fennelly
Robert Fenton
Soldano Ferrone
Jorge Filmus
Howard Fine
James Finke
Jonathan Finlay
Richard Fisher
Kathleen Flanders
J. Fleming
Tito Fojo
Judah Folkman
Kwun Fong
Kenneth Foon
Richard Ford
Arthur Frankel
Arnold Freedman
Eileen Friedman
Minoru Fukuda
Leo Furtch

D
Janice Gabrilove
Varsha Gandhi
Bernd Gansbacher
Harinder Garewal
Adi Gazdar
Clementina Geiser
Edward Paul Geismann

E
Janet Eary
Alan Eastman
J. Eckardt

F

G

1May 1, 1994 through October 1, 1995.
Stephen George
Eugene Gerner
Giuseppe Giaccone
Stephen Gillies
D. Gary Gilliland
L. M. Glode
Peter Goedegebuure
Alec Goldenberg
David Goldenberg
G. J. Goldenberg
Lori Goldstein
Jared Gollob
Gary Goodman
M. Gordon
Marshall Goren
Michael Gottesman
Jennifer Grandis
Stefan Grant
Stephen Graziano
William Greco
Joel Greenberger
Geoffrey Greene
Jean Grem
Elizabeth Grimm
T. M. Grogan
Richard Grolia
Michael Grossbard
H. Barton Grossman
Eric Groves
William Gullick

D. Hochhauser
David Hockenberg
Robert Hoffman
Susan Flamm Honig
Gabriel Hortobagyi
Kathryn Horwitz
Alan Houghton
Peter Houghton
Lou Houston
Clifford Hudis
Mien-Chie Hung
Kim Hustin
Nancy Hynes

Claudine Isaacs
William Issacs
Lyonel Israels

Ann Jakubowski
C. David James
John Janik
Jin Jen
Scott B. Jennings
Suresh Jhanwar
Robert Jilka
Bruce Johnson
Michael Johnson
Joseph Jurcic

D. Kadmon
Greg Kalemkerian
Robert J. Kaner
Philip Kantoff
Arlene Kantor
Bela Kanyicska
Michael Kastan
Michael Kelley
Nancy Kemeny
Michael John Kennedy
Kenneth Kinzler
Michael Klagsbrun
David Kleiner
Eugenie Kleiman
D. Klimstra
Wayne Koch
Steven Koester
William Kopp
Jason Koutcher
Mark Kris
Susan Krown
J. Krueger
F. P. Kuhajda
Rakesh Kumar

Paul Lange
Richard Larson

Lawrence Leichman
W. R. Leopold
John Letterio
Victor Levin
Arnold J. Levine
BARRY Levinson
Brian Leyland-Jones
Ti Lin
Charles Link
Ilona Linnoila
Scott Lippman
Alan List
Philip Livingston
Albert LoBuglio
Janina Longtime
G. Lopez-Berestein
M. Scott Lucia
Ruth Lupe
LUCIO Luzzatto
Henry Lynch

Mack Mabry
E. Gregory MacEwen
Frank Maley
Sanford Markowitz
John Marsh
Daniel Martin
Peter Maslak
Joan Massague
Eric Masson
Lynn Matrisian
Dana Matthews
Ursula Matulonis
Helena Maurer
Amitabh Mazumder
John McBain
T. J. McDonnell
David McLaughlin
Joseph McPhillips
Paul Meltzer
S. Meltzer
Adrian Merlo
Neal Meropol
Roland Mertelsmann
Frederick Meyers
Paul Meyers
R. Meyn
Mary Beth Mientin
James Mier
Steven Miles
Antonius A. Miller
Langdon Miller
Bruce Minsky
Malcolm S. Mitchell
Malcolm Moore
Briggs Morrison
Jeffrey Moscow
Robert Motzer
Franco Muggia
J. J. Mule
David Munn
John R. Murphy

James Lee Murray
V. Murty
Ruth Muschel

David Nanus
Kathryn Nason-Burchenal
Mark Nelson
Robert Newman
Garth Nicolson
Stephen Newman
Perry Nimer

James O'Brien
M. J. O'Connell
Peter O'Connell
Patrick O'Connell
Herbert Oettingen
Edward H. Oldfield
David Olson
James Olson
Joost Oppenheim
John Ortolano
Joyce O'Shaughnessy
Thomas O'Shea

David L. Page
Lee Pai
Larry Panasci
G. Parmiani
Sybill Patan
Richard Pazdur
Anthony Pegg
Roman Perez-Soler
Manuel Peruchio
G. Peters
William Peters
David Pfister
Lawrence Piro
Giuseppe Pizzorno
Leonidas C. Plataniou
Alan Pollack
Yves G. Pommier
Milan Potmesil
Philip Potter
William C. Powell
Garth Powis
Elizabeth Poynor
Janet Price
Hans Prochaska

Robert Radinsky
William J. Ramsey
R. Beverly Raney
J. Sambusiva Rao
George Raptis
Frank J. Rauscher III
AUTHOR INDEX

Volume 1

A

Abe, O., 1537
Adzick, N. S., 327
Aeppli, D., 913
Aguzzi, A., 207
Aherne, G. W., 391
Aksentijevich, I., 447
Alberti, D., 493
Albertini, M., 483
Allard, P., 1195
Allay, E., 519
Allison, R. S. H., 129
Alfred, D. C., 1203
Alvarez, R. D., 1571
Alvord, W. G., 1327
Ambus, U., 287
Amiel, A., 823
Amplot, P., 1623
Amos, C. J., 1617
Andersen, J. A., 881
Anderson, P. S., 313
Andreeff, M., 583
Andrulis, I. L., 907, 1611
Anna, C., 687
Anzai, H., 1095
Aplan, P. D., 459
Archer, G. E., 1545
Argenta, P. A., 327
Aschele, C., 955, 1337
Assikis, V. J., 467
Athanasiadis, I., 973
Atwood, A., 847
August, D. A., 351

B

Baak, J. P. A., 81
Bagnato, A., 1059
Bahn, H., 775
Bailey, N., 1275
Baker, L. H., 831, 1487
Baker, M. A., 935
Baker, T. M., 1133
Baldo, C., 1337
Ball, E. D., 425, 607, 965, 1319
Balmes, J., 1275
Banerjee, S., 1421
Barbarascu, M., 189
Barbhaiya, R. H., 105
Baron, J.-C., 1385
Barrett, J. C., 687
Bartel, S., 269
Bartemes, K., 805
Baselga, J., 161
Basser, R. L., 715
Bates, S. E., 1581
Batra, S. K., 859
Bauer, J. J., 1295
Baye, R., 1421
Bechhofer, R., 481
Bedi, G., 257
Beers, T., 1285
Begley, C. G., 715
Beilstein, P., 813
Bellamy, W. T., 1563
Bello, D., 1089
Benhar, I., 1023
Bennett-Baker, P., 539
Benson, A. B., III, 1133
Berезин, F. K., 1133
Berger, J. S., 223
Berger, N. A., 223, 369
Bergeron, R. J., 847
Berges, R. K., 473
Berkowitz, I., 699
Bernard, S., 621
Bernacki, R. J., 847
Bernard, P., 1195
Bernstein, Z., 1285
Berry, D., 699
Bertino, J. R., 631, 955
Bertolino, S., 955
Bevilacqua, P., 189, 1375
Bhalla, K., 559, 1399
Bharti, A., 269
Bhattacharya-Chatterjee, M., 1285
Bhatia, U., 573
Bianco, A. R., 49, 161, 377
Bianco, C., 49, 161, 377
Bièche, I., 123
Bielenberg, D., 19
Biggar, R. J., 257
Bignier, D. D., 859, 1545
Bitran, J. D., 185
Bittner, M., 11
Bloom, E., 607
Bloomfield, C. D., 459
Blumberg, P. M., 1581
Boddy, A. V., 1275, 1479
Boersma, T., 1301
Bolli, E. A., 955
Bondy, M. L., 1617
Bonoldi, E., 1375
Booocock, C. A., 313
Borach, P., 189, 1375
Borchart, A., 481
Bosman, F. T., 1301
Bottardi, S., 147
Boudouhas, S., 797
Bova, G. S., 1471
Boyd, J., 539
Boynton, J., 1223
Brookefield, X. O., 1171
Breimer, D. M., 1252
Breitman, T. R., 637
Brennan, E. J., 665
Brenner, D. E., 351
Brent, T. P., 1359
Brett, S., 147
Brooks, D., 1259
Broossard, E. K., 1503
Brown, L. F., 1209
Broxierman, H. J., 81
Bruner, J. M., 1617
Brüning, E. A., 1079
Bruno, S., 1337
Bruynseels, J., 287
Buzzi, P., 955
Bucana, C. D., 19, 1095
Buchdunger, E., 813
Buchegger, F., 565
Büchler, M. W., 1413
Bullock, G., 559, 1399
Burgaad, J.-L., 1429
Burger, H., 1301
Burke, P. J., 295
Burkert, W., 775
Burrows, F. J., 1623
Busch, R., 199
Busssel, A., 1463
Bussemakers, M. J. G., 1471
Buzdar, A., 691
Byrd, D. R., 1071

C

Cacace, A., 113
Caffo, O., 189
Calderelli, D. D., 527
Calvert, A. H., 1275, 1479
Calvete, J. A., 1275
Calzone, K. A., 539
Camarda, M., 1495
Campion, M., 1139
Cannistra, A. S., 333
Cao, S., 839
Cap, B., 791
Capitelli, P., 1503
Caraglia, M., 161
Carbon, D. P., 1119
CarMichel, M., 473
Caron, P. C., 63
Carraquillo, J. A., 1447
Carver, J. F., 935
Casey, G., 1223
Catt, K. J., 1059
Cavalli, F., 1517
Cebon, J., 715
Chakraborty, M., 1285
Chamberlain, J., 539
Champére, M.-H., 123
Char, D. H., 481
Chastre, E., 147
Chatterjee, S., 369
Cheever, M. A., 1071
Chen, G. Z. J., 705
Chen, J., 425, 1319
Chen, L. B., 621
Chen, P., 1557
Chen, T., 129
Chen, W., 1071
Chenvert, T. L., 643
Cheng, M.-F., 223
Cheng, R., 1447
Cheresh, P., 1209
Cheshire, P. J., 33
Chiang, L.-C., 113
Chinchilli, V. M., 551
Chiozza, E. A., 1171
Christensen, J. I., 881
Chung, Y., 1447
Church, J. M., 1421
Ciardiello, F., 49, 161, 377
Ciemik, B. H. K., 1119
Ciemik, J. F., 1119
Cisek, L., 473

D

Clark, D. A., 1145
Clark, L., 965
Clark, R. M., 287
Claxton, D. F., 583, 1051
Clemeninn, M., 1275
Cockerell, C. J., 1119
Cohen, A. M., 899
Cohen, B. B., 945
Cohen, D., 545
Cole, K. A., 797
Coleman, N., 621
Coleman, R. E., 921
Collins, C., 1455
Collins, F. S., 539
Collins, J. M., 399
Collins, J. P., 715
Collins, S. L., 95
Comoglio, P. M., 147
Consoli, U., 583
Coon, J. S., IV, 527
Corden, L., 1203
Cordon-Cardo, C., 545
Costa, S., 1125
Costanza, M. E., 699
Coto, E., 1043
Cowan, K., 295
Cowan, K. H., 71, 129, 235, 889, 1447
Crawford, E. D., 57
Crebbin, V., 551
Creekmore, S. P., 1327
Crow, J., 1267
Crump, M., 287
Cunningham, J. E., 1617
Curiel, D. T., 1571
Curley, E. M., 551
Curt, G., 1447
Curtis, B. D., 1327
Cussenot, O., 1385
SUBJECT INDEX

Volume 1

Annamycin
liposomal, preclinical toxicity, 1369

Antibody: see also Monoclonal antibody
anti-idiotypic
T-cell lymphoma therapy, immune responses, 1285
antitransferrin receptor, 42/6
phase Ia trial, 1259
bispecific, 251 × 22 (anti-CD3 × anti-CD6)
acute myeloid leukemia cell lysis, 1319
chimeric
anti-EGFR (C225), biological efficacy, human tumor xenograft model, 1311
p53 protein, various cancer types, 1463
ras proteins, colon cancer, 1071
specific mode, human endothelial cells immunotoxin-mediated vascular leak syndrome, 1589

Anticancer agents
carbohydrate processing inhibitors, 935

Antifolate
antipurine
lometrexol, with oral folic acid supplement, pharmacokinetics, 1479
thymidylate inhibitors
AG337, 24-hour study, 1275
antitumor effects, human soft tissue sarcoma cell lines, 631

Antigen
high molecular weight-melanoma
associated
mimicry by mouse anti-idiotypic mAb
MK2-23, malignant melanoma, 705
highly restricted T-cell anti-idiotypic antibody mimicking, T-cell lymphoma therapy, 1285
prostate-specific
human prostate cancer cell invasion facilitation, 1089
tumor-associated
prognostic factors, transitional cell bladder carcinoma, 1195

Anti-idiotypic therapy
T-cell lymphoma, immune responses, 1285

Antileukemic drugs
novel
3-hydroxysterol and dibezine, 823

Antineoplastic agents
suramin
cellular pharmacology, 509

Antipurine antifolate
lometrexol, with oral folic acid supplement, pharmacokinetics, 1479

Antitransferrin receptor antibody 42/6
phase Ia trial, 1259

α5-Intyrrpsin
proteolysed
urinary excretion, acute myeloid leukemia, 199

Apoptosis
cell cycle control, nitrogen mustard, 873
drug-induced
c-Jun induction and, human acute leukemia cells, 559

high molecular weight DNA fragmentation, leukemia cells, 1005
growth factor-induced
prevention by PML/RARA, acute promyelocytic leukemia, 583
taxol-induced
protein kinase modulators and, human leukemic cells, 1399

1-β-D-Arabinofuranosylcytosine
sensitivity, acute myeloid leukemia, 81

Aromatase
letrozole inhibition, postmenopausal breast cancer patients, 1511
vorozole inhibitor advanced breast cancer therapy, phase II study, 287

Asciites
ovarian cancer
ovarian cancer activating factor, characterization, 1223

Astrocytomias
PAX5 expression, 207

Ataxia telangiectasia
heterozygote response to fractionated radiation, 785

Autoantibodies
anti-DNA topoisomerase II, liver cancer, 417
p53, glioma, 775

Autologous peripheral blood stem cells
transplantation and immunotherapy, immediate posttransplant, 607

5-Aza-2'-deoxycytidine
-induced carcinogenesis
phenylacetate suppression, 865

B

Bacterial alkyltransferase
gene expression, murine bone marrow, 1359

bcl-2
expression
and node-positive breast cancer outcome, 189
prognostic value, stage II colon carcinoma, 1103
VP-16-resistant cells, 1391

B1(dsFv)PE38
immunotoxin characterization, human carcinoma xenografts, nude mice, 1023

bFGF: see Fibroblast growth factor, basic
B1(Fv)PE38
immunotoxin characterization, human carcinoma xenografts in nude mice, 1023

Bis-aceto-amine-dichloroacyclohexylamine platinum(IV)
transport, ovarian carcinoma cell lines, 981

4,5-Bis(4-fluoroanilino)phthalimide
EGF-R kinase inhibitor, in vivo antitumor effects, 813

Bladder carcinoma
v-erbB-2 amplification, prognostic value, 1189
MRP expression, 1301
superficial
oncotxin TP40, phase I clinical study, 57
transitional cell
human papillomavirus, 435
tumor-associated antigens, prognostic factors, 1195
Blood: see Peripheral blood
Blood-brain barrier
osmotic disruption
irradiation and chemotherapy, rodent model, 731
B3-LysPE38
dosage effect on survival, carcinomatous meningitis rat model, 1545
Bone marrow
alkyltransferase gene expression, murine, 1359
carcinoma cell removal, rhodamine 123, 621
liposomal annamycin toxicity, preclinical, 1369
nascent DNA
9-aminocamptothecin effects, 1345
transplant
CSA and, combined with chemotherapy, phase I clinical trial, 1495
Brain tumors
intracerebral rat 9L model
growth kinetics and treatment response, MRI study, 643
intracranial gliomas
gene therapy, MRI and 1H MRS study, 651
VP-16-resistant cells
topoisomerase II, Bel-2, and p53 expression, 1391
BRCA1
germline mutations and loss of
heterozygosity, early onset breast and ovarian cancer, 539
Breast
epithelial cells
cytotoxic effects of adenovirus-mediated
wild-type p53 expression, 889
MDM2 mRNA expression, 715
hypersensitivity to topoisomerase II inhibitors, 49
Breast carcinoma
adjuvant multicycle high-dose chemotherapy, 715
advanced
amotidane treatment, Cancer and Leukemia Group B study, 699
thioTEPA combined with pentoxifylline, dose escalation, 791
vorozole therapy, phase II study, 287
advanced metastatic
TGF-β1 circulation, 129
cathepsin B and L, prognostic value, 741
chromosome 1q multiple genetic alterations, 123
cloned ER variant mRNA expression and, 155
eyearly onset
germline BRCA1 mutations and loss of heterozygosity, 539
ER
"c-myb" posttranscriptional regulation, 235
insulin receptor substrate 1 overexpression, 1429
intraductal
gene alterations pattern, 261
invasive
chromosome 20q13 amplification, prognostic implications, 1455
flow cytometric DNA analysis, 881
medical outcomes of care, health maintenance organization and fee-for-service patients, 179
metastatic
pirarubicin combined with 5-fluorouracil and cyclophosphamide, phase II study, 1267
rapidly cycled high-dose alkylators, 1267
MRP expression, 1301
node-positive
bcl-2 protein expression and outcome, 189
p53 mutations
CIP1/WAF1 expression, 907
tamoxifen resistance, 1203
paclitaxel therapy, 247
P-glycoprotein phosphorylation, bryostatin 1 and, 1581
postmenopausal
aromatase inhibition by letrozole, 1511
serum hepatocyte growth factor concentrations, 1031
stage IV
ifosfamide and doxorubicin with rhG-CSF, phase I study, 185
tenascin expression, 1035
urokinase-type plasminogen activator receptor, prognostic significance, 1079
vascular endothelial growth factor and platelet-derived endothelial cell growth factor coexpression, 961
Wnt5a cloning, expression, and up-regulation, 215
Breast carcinoma in situ
flow cytometric DNA analysis, 881
Broccoli
salychary chemopreventive enzyme induction, 1153
Bryostatin 1
and P-glycoprotein phosphorylation, breast cancer cells, 1581
Bystander effect
cyclophosphamide/P450 2B1 gene therapy, 1171
Cancer: see Carcinoma
Cancer and Leukemia Group B studies
amotidane, advanced breast cancer, 699
TAL1 rearrangements, adult acute lymphoblastic leukemia, 459
Carbohydrate
-learning, processing inhibitors, anticancer agents, 925
Carboplatin/etoposide
recombinant IL-3 before and after, phase I trial, 1139
Carboxyamido-triazole
metabolism, human liver tissue and humans, 399
oral, pharmacokinetics, 797
Carcinogenesis
5-aza-2'-deoxycytidine-induced phenylacetate suppression, 865
Carcinoma
advanced
ifosfamide and glutathione, 1525
anti-CD3 mAb and interleukin 2 therapy of, phase I study, 481
8-chloro-cyclic AMP immunological effects, phase I clinical study, 377
human xenografts
B1(Fv)PE38 and B1(dsFv)PE38 immunotoxin characterizations, nude mice, 1023
-included gene
differential display identification, 1209
MRP expression, human, 1301
p53 antibodies, 1463
patient survival
histoculture drug-response assay and, 1537
removal from bone marrow, rhodamine 123, 621
Carcinoma, aerodigestive
retinoid chemoprevention, basic research to clinics, 677
Carcinoma, bladder
c-erb-B2 amplification, prognostic value, 1189
MRP expression, 1301
Carcinoma, breast
adjuvant multicycle high-dose chemotherapy, 715
advanced
amotidane treatment, Cancer and Leukemia Group B study, 699
thioTEPA combined with pentoxifylline, dose escalation, 791
vorozole therapy, phase II study, 287
advanced metastatic
TGF-β1 circulation, 129
cathepsins B and L, prognostic value, 741
chromosome 1q multiple genetic alterations, 123
cloned ER variant mRNA expression and, 155
early onset
germline BRCA1 mutations and loss of heterozygosity, 539
ER
"c-myb" posttranscriptional regulation, 235
insulin receptor substrate 1 overexpression, 1429
invasive
chromosome 20q13 amplification, prognostic implications, 1455
flow cytometric DNA analysis, 881
MDM2 mRNA expression, 71
medical outcomes of care, health
maintenance organization and fee-for-
service patients, 179
metastatic
pirarubicin combined with 5-fluorouracil
and cyclophosphamide, phase II study, 691
rapidly cycled high-dose alkylators, 1267
MRP expression, 1301
node-positive
bcl-2 protein expression and outcome, 189
p53 mutations
CIP1/WAF1 expression, 907
tamoxifen resistance, 1203
paclitaxel therapy, 247
P-glycoprotein phosphorylation, brystatin
1 and, 1581
postmenopausal
aromatase inhibition by letrozole, 1511
serum hepatocyte growth factor
concentrations, 1031
stage IV
ifosfamide and doxorubicin with rhG-
CSF, phase I study, 185
tenacin expression, 1035
urokinase-type plasminogen activator
receptor, prognostic significance, 1079
vascular endothelial growth factor and
platelet-derived endothelial cell
growth factor coexpression, 961
Wnt-5a cloning, expression, and up-
regulation, 215
Carcinoma, cervical
HLA-6-induced cachexia, human xenograft, 1353
HSP70 levels, 1217
Carcinoma, colon
alkyltransferase activity, 519
antibody to ras proteins, 1071
chemotherapy response, mutant K-ras and
441
N1,N2-diethylnorspermine efficacy
against, preclinical, 847
EGF-R expression
and metastatic potential, 19
FUra and IFN-β, 1337
iododeoxyuridine radiosensitization
modulation by 5′-aminothymidine and
leucovorin, 407
metastasis-related genes, multiparametric
in situ mRNA hybridization analysis, 1095
metastatic
131I-labeled CC49 with deoxypergualin,
pilot radioimmunotherapy trial, 1503
MRP expression, 1301
stage II
bcl-2 oncprotein expression, prognostic
value, 1103
thymineless death
2′-deoxyadenosine-5′-triphosphate/
thymidine-5′-triphosphate ratio and,
723
Carcinoma, colorectal
advanced
schedule-selective biochemical
modulation of FUra, 955
Carcinoma, epithelial ovarian
advanced
thymineless
5-fluorouracil prodrug therapy, 839
ornithine decarboxylase and prognosis, 665
recombinant immunotoxin C242Fab’-
PE38QQR, 1015
TIMP-1 RNA expression
and liver metastases, 899
Carcinoma, endometrial
and tamoxifen, 467
Carcinoma, epithelial ovarian
advanced
tumor-infiltrating lymphocyte adoptive
immunotherapy, 501
progesterone receptor content
11q22 loss of heterozygosity and, 945
Carcinoma, gastrointestinal
telomerase activity, 1245
Carcinoma, head and neck
CD34+ cells, 95
Carcinoma, hematological
radioimmunotherapy, problems and
progress, 1439
Carcinoma, hepatic
autoantibody to DNA topoisoerase II,
417
Carcinoma, kidney
MRP expression, 1301
Carcinoma, liver
autoantibody to DNA topoisoerase II,
417
Carcinoma, lower respiratory tract
p53 mutations, 763
Carcinoma, non-small cell lung
advanced
TRA/IFN-α, phase II study, 973
chromosome 9p21 homozygous deletions,
687
chronic oral etoposide pharmacology, 1517
MRP expression, 1301
p15 and p16 mutations, 687
Carcinoma, ovarian
activating factor, characterization, 1223
advanced
dose intensity, 575
autocrine endothelin-1 growth factor
effects, 1059
CD44 heterogeneity, 333
cisplatin and JM216 transport, 981
DF3-P expression, 565
N1,N2-diethylnorspermine efficacy
against, preclinical, 847
early onset
germine BRCA1 mutations and loss of
heterozygosity, 539
ovarian
ganociklovir sensitization, HSV-TK gene,
1571
HSP27 expression, 1603
MRP expression, 1301
Carcinoma, pancreatic
erbB-3 expression, 1413
Carcinoma, prostatic
cell invasion
prostate-specific antigen facilitation,
1089
cell kinetic changes, 473
chromosome 7q31 loss of heterozygosity,
1385
DNA sequence amplification
identified by chromosome
microdissection, prognostic
implications, 11
DU-145 cells
urokinase-type plasminogen activator,
receptor
expression, 747
matrix degradation
inhibition by retinoic acid, 755
MRP expression, 1301
p53 nuclear protein expression, prognostic
marker, 1295
vitamin D receptor expression, 24-
hydroxylase activity, and growth
inhibition by 1α,25-dihydroxyvitamin
D3, 997
Carcinoma, renal
MRP expression, 1301
Carcinoma, renal cell
EGF-R and TGF-α expression, 913
MDR1 expression, 1613
Carcinoma, small cell lung
chronic oral etoposide pharmacology, 1517
lysis
Lys3-bombesin and mAb 22
immunconjugate induction, 425
Carcinoma, squamous cell
EGF-R ectodomain, 551
esophageal
MRP expression, 1301
p53 mutations, MDM2 amplification,
and HPV infection, 769
head and neck
cell kinetics, 527
dendrogram, pretreatment p53 expression and,
1407
GM-CSF-secreting, CD34+ cells, 95
mAb E48 biodistribution, 277
p16 and p53 loss of heterozygosity and
mutations, 1043
predictive and prognostic markers, 1375
tumor targeting, mAb U36, 591
lung
K-ras mutations, 359
radiation-induced proliferation with EGF,
1557
Carcinoma, testicular
MRP expression, 1301
Carcinoma, transitional cell
bladder
human papillomavirus, 435
tumor-associated antigens, prognostic
factors, 1195
Carcinoma, upper respiratory tract
p53 mutations, 763
Carcinoma in situ, breast
flow cytometric DNA analysis, 881
Carcinomatosus meningitis
LMB-1 dosage effect on survival, rat
model, 1545
Cathepsin B
prognostic value, human breast cancer,
741
Cathepsin L
prognostic value, human breast cancer,
741
Cations
rhodamine 123
removing carcinoma cells from bone
marrow, 621
CC49
131I-labeled, and deoxypergualin,
metastatic colon carcinoma, 1503
Chemoimmunotherapy

Chemoradiation therapy
head and neck squamous cell carcinoma, predictable and prognostic markers, 1375

Chemoresistance: see also Resistance
WAF1/Cip1 levels and, acute myelogenous leukemia, 1051

Chemosensitivity
acute myeloid leukemia
in vivo interleukin 3 and, 295

Chemosensitization
P-glycoprotein, SCID human myeloma xenograft model, 1563

Chemotherapy
carboplatin/etoposide
recombiant IL-3 before and after, phase I trial, 1139
combined with CsA and bone marrow transplant, phase I clinical trial, 1495
cranial irradiation and, rodent model, 731
dose intensity, advanced ovarian cancer, 575
multicycle high-dose, breast cancer, 715
pirarubicin combined with 5-fluorouracil and cyclophosphamide, metastatic breast cancer, 691
response
mutant K-ras and, colon cancer, 441

Chimeric antibody
anti-EGFRT (C225), human tumor xenograft model, 1311

Chimeric proteins
C242F(ab')-PE38QQR recombinant anti-colorectal cancer immunotoxin, 1015
hIL-13-PE38QRQ human glioma sensitivity, 1253

8-Chloro-cyclic AMP
phase I clinical study, 377

tumor cell growth inhibition, 161

2-Chloro-2'-deoxyadenosine
cellular pharmacokinetics, leukemia, 385
resistance, lymphoid cell lines, 391

Chlorothalidone

diuretics, 1359

genetic, breast cancer, 123

Chromosome microdissection
DNA sequence amplification identification, prostate cancer, 11

Chromosome 1q
multiple alterations, breast cancer, 123

Chromosome 7q31
loss of heterozygosity, prostate cancer, 1385

Chromosome 9p21
homoezygous deletions, non-small cell lung cancers, 687
loss of heterozygosity and mutations, head and neck squamous cell carcinoma, 1043

Chromosome 11q22
loss of heterozygosity and progesterone receptor content, epithelial ovarian cancer, 945

Chromosome 17p13
loss of heterozygosity and mutations, head and neck squamous cell carcinoma, 1043

Chromosome 20q13
amplification, invasive breast cancer, 1455

CIPI/WAF1
mRNA expression, breast carcinoma with p53 mutations, 907

Cisplatin
combined with liposome-encapsulated muramyl tripeptide
phosphatidylethanolamine, canine osteosarcoma, 1595
dose intensity, advanced ovarian cancer, 575
resistance
plasma membrane protein, ovarian carcinoma cell lines, 981
transport, ovarian carcinoma cell lines, 981
c-jun
induction
and apoptosis, human acute leukemia cells, 559

Clone 4 estrogen receptor variant
mRNA expression, and breast cancer, 155

Cloning
AIDS-related Kaposi’s sarcoma, 257
Wnt5, human breast cancers, 215
c-met
overexpression and amplification, colorectal cancer, 147
c-myb
posttranscriptional regulation, ER+ breast cancer cells, 235

Coffee
salivary chemopreventive enzyme induction, 1153

Colon adenocarcinoma
FUr-leucovorin activity, xenografts, 33

Colon carcinoma
alkyltransferase activity, 519
antibody to ras proteins, 1071
chemotherapy response, mutant K-ras and, 441
N′,N′-diethylaminoethylperme efficacy against, preclinical, 847
EGFR expression
and metastatic potential, 19
FUra and IFN-β, 1337
iododeoxyuridine radiosensitization modulation by 5′-aminouridine and leucovorin, 407
metastasis-related genes, multiparametric in situ mRNA hybridization analysis, 1095
metastatic
131I-labeled CC49 with deoxyspergualin, pilot radioimmunotherapy trial, 1503
MRB expression, 1301
stage II
bcl-2 oncoprotein expression, prognostic value, 1103
thymidine death
2′-deoxyadenosine-5′-triphosphate/thymidine-5′-triphosphate ratio and, 723

Colon-stimulating factor 1
and endometrial adenocarcinoma etiopathogenesis, 313

Colorectal carcinoma
advanced
schedule-selective biochemical modulation of 5-fluorouracil, 955
c-met overexpression and amplification, 147
5-fluorouracil prodrug therapy, 839
ornithine decarboxylase and prognosis, 665 recombinant immunotoxin C242Fl(ab')-PE38QQR, 1015 TIMP-1 RNA expression and liver metastases, 899 Colorectal lesions telomerase activity, 1245 Colorectal tumorigenesis elevated RNase L levels, 1421 Cranial irradiation and chemotherapy, rodent model, 731 Cryopreservation tumor-infiltrating lymphocytes, adoptive immunotherapy, advanced epithelial ovarian cancer, 501 Cyclic AMP-dependent protein kinase type I topoisomerase II inhibitor hypersensitivity, human breast cells, 493 Cyclophosphamide combined with pirarubicin and 5-fluorouracil, metastatic breast cancer, 691 Cyclophosphamide/cytochrome P450 2B1 therapy, bystander effect, 1171 Cycloporine A and bone marrow transplant combined with chemotherapy, phase I clinical trial, 1495 Cysteine proteases cathepsins B and L, breast cancer, 741 Cytarabine cellular metabolism, modulation by G-CSF, 169 Cytochrome P450 2B1 cyclophosphamide gene therapy, bystander effect, 1171 Cytokine response multinuclear vesicle muramyl tripeptide phosphatidylethanolamine treatment, 493 Cytotoxicity chloroethyl nitrosourea ada gene therapy, murine bone marrow, 1359 humanized mAb M195, myelogenous leukemia, 63 monocye multinuclear vesicle muramyl tripeptide phosphatidylethanolamine treatment, 493 water-insoluble camptothecin congeners, preclinical studies, 1235

D

D1694 antitumor effects, soft tissue sarcoma cell lines, 631 D54 cells topoisomerase II, Bcl-2, and p53 expression, 1391 Death: see also Apoptosis thymineless 2'-deoxyadenosine-5'-triphosphate/thymidine-5'-triphosphate and, colon carcinoma cells, 723

2'-Deoxyadenosine-5'-triphosphate/thymidine-5'-triphosphate and thymineless death, colon carcinoma cells, 723 2'-Deoxyxylulonate kinase deficiency and 2-chloro-2'-deoxyadenosine resistance, lymphoid cell lines, 391 Deoxyribonucleoside 5'-triphosphate and thymineless death, colon carcinoma cells, 723 Deoxyxylulonate 111-labeled CC49 combined with chemotherapy, metastatic colon carcinoma, 1503 DF3-P expression, human ovarian carcinomas, 565 cis-Diaminedichloroplatinum(II): see Cisplatin Dibezine antileukemic effects, 823 5,10-Dideazatetrahydrofolic acid antitumor effects, soft tissue sarcoma cell lines, 631 (6R)-5,10-Dideazaa-5,6,7,8-tetrahydrofolic acid with oral folic acid supplement, pharmacokinetics, 1479 N',N'-Diethylmorpholine antitumor efficacy, preclinical, 847 Differential display human carcinoma-induced gene identification, 1209 3,4-Dihydro-2-amino-6-methyl-4-oxy-5-(4-pyridyldithio)quinazolone dihydrochloride pharmacokinetics and pharmacodynamics, 24-hour study, 1275 N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N'-methylamino-2-thenoyl-L-glutamic acid: see D1694 Dihydropyrimidine dehydrogenase tumor target for fluorouracil modulation, 991 1α,25-Dihydroxyvitamin D₃, growth inhibition, prostatic carcinoma cell lines, 997 DNA nascent bone marrow 9-aminocamptothecin effects, 1345 DNA analysis flow cytometric, breast cancers, 881 DNA fragmentation high molecular weight, leukemia cell apoptosis, 1005 DNA sequence amplification chromosome microdissection, human prostate cancer, 11 DNA topoisomerase I inhibitors, mutagenic activity, 369 DNA topoisomerase II autotubidity, liver cancer, 417 expression, VP-16-resistant cells, 1391 inhibitors hypersensitivity, human breast cells, 49 Dose intensity advanced ovarian cancer, 575 Doxorubicin combined with ifosfamide and rhG-CSF, stage IV breast cancer, 185 metabolism, subthalic liver injury and, 351 Drug resistance: see Multidrug resistance Drugs histoculture response assay and cancer patient survival, 1537 clinical applications, 305 -induced apoptosis c-jun induction and, human acute leukemia cells, 559 -resistant solid tumors chemotherapy combined with CsA and bone marrow transplant, phase I clinical trial, 1495 DT-diaphorase salivary, induction, 1153 DU-145 cells urotensin-type plasminogen activator retinoic acid modulation, 747 Ductal carcinoma in situ flow cytometric DNA analysis, 881 Dysplasia cervical epithelium CD44 splice variants expression, 1125 E

E48 biodistribution, head and neck cancer, 277 Ectodomain epidermal growth factor receptor, squamous cell carcinoma, 551 EGFR: see Epidermal growth factor receptor Endoglin vascular endothelial cell up-regulation, human solid tumors, 1623 Endometrial adenocarcinoma etiopathogenesis, colony-stimulating factor 1 and, 313 Endometrial carcinoma and tamoxifen, 467 Endothelial cells immunotoxins targeting -mediated vascular leak syndrome, 1589 vascular endoglin up-regulation, human solid tumors, 1623 Endothelial growth factor vascular expression, breast cancer, 961 Endothelin-1 autocrine growth factor effects, ovarian carcinoma cells, 1059 Enzymes chemopreventive salivary, induction, 1153 Eosinophils activation IL-4 therapy, 805 Epidermal growth factor radiation-induced proliferation, human squamous cancer cells, 1557 receptors 4,5-bis(4-fluorooctyl)imidazole inhibitor, in vivo antitumor effects, 813 chimeric antibody, biological efficacy, human tumor xenograft model, 1311 ectodomain, squamous cell carcinoma, 551 expression, and metastatic potential, human colon carcinoma cells, 19 expression, prostatic neoplasms, 545
expression, renal cell carcinoma, 913
mAb 528, tumor cell growth inhibition, 161
mutant, immunotoxins that target, 859

Epithelial cells
mammary
cytotoxic effects of adenovirus-mediated
wild-type p53 expression, 889
MDM2 mRNA expression, 71

Epithelial ovarian cancer
advanced
adoptive immunotherapy with tumor-
infiltrating lymphocytes, 501
progestosterone receptor content
11q22 loss of heterozygosity and, 945

Epithelium, cervical
CD44 splice variants expression, 1125

Eptoposide
chronic oral
pharmacology, small cell and non-small
cell lung cancer, 1517
combined with carboplatin
recombinant IL-3 before and after,
phase I trial, 1139
30-minute infusion, phase I study, 105
resistance
topoisoerase II, Bcl-2, and p53
expression, brain tumor cell lines, 1391

Exotoxins
Pseudomonas
human IL-13-, human glioma
sensitivity, 1253
immunotoxins containing, -mediated
vascular leak syndrome, 1589
recombinant F(ab') C242, anti-
colorectal cancer immunotoxin, 1015

Experimental intracranial tumors
gliomas
gene therapy, MRI and 1H MRS study, 651
rat 9L model
growth kinetics and treatment response,
MRI study, 643

F

F(ab')2
E48
biodistribution, head and neck cancer, 277

F(ab') C242-Pseudomonas exotoxin
recombinant anti-colorectal cancer
immunotoxin, 1015

FcyRI
mAb 22 against
Lys⁺-bombesin immunonjugate
induction of lysis, small cell lung
carcinoma, 425

Fee-for-service plans
medical outcomes of care for breast
cancer, 179

Fenretinide: see N-(4-
Hydroxyphenyl)retinamide

Fibroblast growth factor
basic levels, Wilms' tumor, 327

Fibroblasts
dermal cultures, response to fractionated
radiation, 785

Filgrastim
-mobilized peripheral blood progenitor
cells, breast cancer, 715
rapidly cycled high-dose alkylators,
metastatic breast cancer, 1267

Flow cytometry
DNA analysis, breast cancers, 881

Fludarabine
cellular metabolism, modulation by G-
CSF, 169

5-Fluorouracil
combined with cyclophosphamide and
pirarubicin, metastatic breast cancer, 691
combined with IFN-β, human colon
carcinoma cells, 1337
combined with leucovorin, colon
adenocarcinoma xenografts, 33
combined with recombinant IFN-α, phase
I study, 615
modulation
dihydropyrimidine dehydrogenase
tumoral target, 991
schedule-selective, advanced colorectal
cancer, 955
prodrug, colorectal cancer, 839

Folates
based purine inhibitors
antitumor effects, soft tissue sarcoma
cell lines, 631

Folic acid
oral supplement
leomteroxil with, pharmacokinetics, 1479

Forbeck Cancer Forum on Cell Cycle
Checkpoints
1994 meeting report, 1067

Fura: see 5-Fluorouracil

Fusion proteins
PML/RARα, acute promyelocytic
leukemia, 583

Fv immunotoxins
B1(dsFv)PE38 and B1(Fv)PE38
characterization, human carcinoma
xenografts in nude mice, 1023

G

Ganciclovir
sensitization
HSV-TK gene, ovarian carcinoma cells, 1571
toxicity
gene therapy, MRI and 1H MRS study, 651

Gastric lesions
telomerase activity, 1245

Gastrointestinal cancer
telomerase activity, 1245

G-CSF: see Granulocyte colony-
stimulating factor

Gene therapy
ada, murine bone marrow, 1359
cyclophosphamide/P50 281
bystander effect, 1171
experimental intracranial gliomas, MRI
and 1H MRS study, 651

Genes: see also Oncogenes
bcl-2
protein expression, and node-positive
breast cancer outcome, 189
alkylytransannerase
expression, murine bone marrow, 1359

BRCAl
germline mutations and loss of
heterozygosity, early onset breast and
ovarian cancer, 539

CHIP/4F1
mRNA expression, breast carcinoma
with p53 mutations, 907
c-met
overexpression and amplification,
colorectal cancer, 147
c-myc
posttranscriptional regulation, ER⁺
breast cancer cells, 235

H-ras
mutations, lung cancer, 359

HSV-TK
ganciclovir sensitization, ovarian
carcinoma cells, 1571
and MDR1, retroviral coexpression, 447
recombinant adenoaviral-mediated
deferential, experimental intracranial
gliomas, MRI and 1H MRS study, 651
human carcinoma-induced
differential display identification, 1209

IGF-II
loss of imprinting, prostate, 1471

K-ras
mutations, and chemotherapy response,
colon cancer, 441
mutations, lung cancer, 359

MDR1
combined with P-glycoprotein,
overexpression, acute myeloid
leukemia, 81
expression, renal cell carcinoma, 1611
and herpes simplex virus thymidine
kinase gene, retroviral coexpression, 447
-transduced cells, selective killing by
coexpression of MDR1 and herpes simplex virus thymidine kinase gene, 447
metastasis-related
multiparametric in situ mRNA hybridization analysis, colon carcinoma, 1095
MRP
expression, human cancers, 1301
overexpression, acute myeloid leukemia, 81
p15
mutations, non-small cell lung cancers, 687
p16
loss of heterozygosity, head and neck squamous cell carcinoma, 1043
mutations, head and neck squamous cell carcinoma, 1043
mutations, non-small cell lung cancers, 687
p53
cell cycle control, nitrogen mustard, 873
loss of heterozygosity, head and neck squamous cell carcinoma, 1043
mutations, and tamoxifen resistance, breast cancer, 1203
mutations, breast carcinoma with, CIP1/WAF1 expression, 907
mutations, esophageal squamous cell carcinoma, 769
mutations, head and neck squamous cell carcinoma, 1043
mutations, metastatic prostate cancer, 1111
mutations, upper and lower respiratory tract carcinoma, 763
PAX5
expression, astrocytomases, 207
PML
RARα fusion protein, acute promyelocytic leukemia, 583
rus
and chemotherapy response, colon cancer, 441
TAL1
rearrangements, adult acute lymphoblastic leukemia, Cancer and Leukemia Group B study, 459
Wnt5
cloning, expression, and up-regulation, human breast cancers, 215
Glioma
experimental intracranial gene therapy, MRI and 1H MRS study, 651
hIL-13-PE38QQR sensitivity, 1253
IL-13 receptor overexpression, 1253
p53 autoantibodies, 775
p53 immunoreactivity, prognostic significance, 1617
Glutathione
ifosfamide and, advanced cancers, 1525
Glutathione S-transferases
salivary, induction, 1153
GM-CSF: see Granulocyte-macrophage colony-stimulating factor
Golgi carbohydrate processing inhibitors, anticancer agents, 935
Granulocyte colony-stimulating factor
cytarabine and fludarabine cellular metabolism modulation, 169
recombinant human ifosfamide and doxorubicin with, stage IV breast cancer, 185
Granulocyte-macrophage colony-stimulating factor
secretory cancers
CD34+ cells, 95
Growth factor withdrawal
-induced apoptosis
prevention by PML/RARα, acute promyelocytic leukemia, 583
Growth factors
autocrine endothelin-1 effects, ovarian carcinoma cells, 1059
epidermal radiation-induced proliferation with, human squamous cancer cells, 1557
hepatocyte serum concentrations, breast cancer, 1031
insulin-like II
loss of imprinting, prostate, 1471
platelet-derived endothelial cell expression, breast cancer, 961
transforming α
expression, prostatic neoplasms, 545
expression, renal cell carcinoma, 913
transforming β
expression, AIDS-associated Kaposis’s sarcoma, 1119
receptors expression, AIDS-associated Kaposis’s sarcoma, 1119
transforming β1
circulation, advanced metastatic breast cancer and normal human plasma, 129
vascular endothelial expression, breast cancer, 961
Heat shock protein 70
eexpression, uterine cervix, 1217
Hemangiosarcoma, splenic
liposome-encapsulated muramyl tripeptide phosphatidylylcholamine adjuvant immunotherapy, canine, 1165
Hematological cancer
radioimmunotherapy, problems and progress, 1439
Hematopoietic reconstruction
new approaches, 3
Hepatic cancer
autoantibody to DNA topoisomerase II, 417
Hepatocyte growth factor receptor
Met gene overexpression and amplification, colorectal cancer, 147
serum concentrations, breast cancer, 1031
Herpes simplex virus thymidine kinase gene
ganciclovir sensitization, ovarian carcinoma cells, 1571
and MDR1, retroviral coexpression, 447
recombinant adenoviral-mediated transfer experimental intracranial gliomas, MRI and 1H MRS study, 651
Heterozygosity, loss of
BRCA1, early onset breast and ovarian cancer, 539
chromosome 7q31, prostate cancer, 1385
chromosome 11q22, epithelial ovarian cancer, 945
intraductal breast neoplasms, 261
p16 and p53, head and neck squamous cell carcinoma, 1043
Heterozygotes
ataxia telangiectasia, and fractionated radiation, 785
High molecular weight-
melanoma associated antigen mimicry by mouse anti-idiotypic mAb
MK2–23, malignant melanoma, 705
Histoculture drug-response assay
and cancer patient survival, 1537
clinical applications, 305
HL-60 cells
differentiation
enhancement by N-(4-hydroxyphenyl)retinamide combined with retinoic acid, 637
elimination by monoclonal antibodies, athymic nude mouse leukemia model, 1179
H-ras
mutations, lung cancer, 359
HSP: see Heat shock protein
Human papillomavirus
infection, esophageal squamous cell carcinoma, 769
transitional cell carcinoma, urinary bladder, 435
24-Hydroxylase
activity, prostatic carcinoma cells line, 997
N-(4-Hydroxyphenyl)retinamide combined with retinoic acid enhancement of differentiation and retinololysis, 637
Hypersensitivity: see also Sensitivity
topoisomerase II inhibitors, human breast cells, 49
Immunoglobulin

Immunotherapy: see Interleukin

Imiquimod
combined with doxorubicin and rhG-CSF
stage IV breast cancer, phase I study, 185
and glutathione, advanced cancers, 1525

IL: see Interleukin

Imaging
tumor receptor, Workshop Report, 921

Immune response
antimouse
modulation by deoxythergulin, metastatic colon carcinoma, 1503

Immune suppression
head and neck cancer, 95

Immunoconjugates
Lysy-bombesin and mAb 22
lysis induction, small cell lung
carcinoma, 425

Immunoglobulin A
murine antitransferrin receptor antibody
42/6, phase Ia trial, 1259

Immunoglobulin G
mAb E48
biodistribution, head and neck cancer, 277
mAb U36
tumor targeting, head and neck cancer, 591

Immunoglobulin G1
chimerized with mAb 225
biological efficacy, human tumor
xenograft model, 1311

Immunoglobulin M
mAb PM-81
serotherapy, acute myeloid leukemia, 965

Immunoreactivity
p53, glioma, 1617

Immunotherapy: see also
Radioimmunotherapy

adjuvant
liposome-encapsulated muramyl
tripeptide phosphatidylethanolamine,
canine spleen hemangiosarcoma,
1165

adoptive
tumor cell transplantation and, immediate
posttransplant, 607
tumor-infiltrating lymphocytes,
advanced epithelial ovarian cancer, 501

tumor anti-idiotypic mAb MK2-23,
malignant melanoma, 705

Immunotoxins
anti-colorectal cancer
recombinant C242(ab')-PE38QQR, 1015
B1(dFv)PE38
caracterization, human carcinoma
xenografts in nude mice, 1023
B1(fv)PE38
caracterization, human carcinoma
xenografts in nude mice, 1023
LMB-1 (B3-LysPE38)
dosage effect on survival, carcinomatous
meningitis rat model, 1545

- mediated vascular leak syndrome, 1589
mutant epidermal growth factor receptor,
859

Imprinting, loss of
IGF-II, prostate, 1471

In situ hybridization
multiparametric mRNA analysis
metastasis-related genes, colon
carcinoma, 1095

Infections
HPV, esophageal squamous cell
carcinoma, 769

Injury
liver
doxorubicin metabolism, 351

Insulin
receptor substrate 1 overexpression, breast
cancer, 1429

Insulin-like growth factor II
loss of imprinting, prostate, 1471

α-Interferon
combined with trans-retinoic acid,
advanced non-small cell lung cancer,
973
recombinant
combined with FUra, phase I study, 615

α2a-Interferon
FUra-leucovorin potentiation, colon
adenocarcinoma xenografts, 33

β-Interferon
tethered with FUra, human colon
carcinoma cells, 1337

Interleukin 2
combined with anti-CD3 mAb, phase I
study, 481
combined with IL-4, phase I trial, 1145
mAb M195 cytotoxicity enhancement,
myelogenous leukemia, 63

Interleukin 3
in vivo
impact on acute myeloid leukemia, 295
recombinant
phase I trial, Southwest Oncology
Group Study, 1139

Interleukin 4
combined with IL-2, phase I trial, 1145
eosinophil activation, cancer patients, 805

Interleukin 6
human
- induced cachexia, human uterine
cervical carcinoma xenograft, 1353

Interleukin 13
human
-Pseudomonas exotoxin, human glioma
sensitivity, 1253
receptors
overexpression, human glioma cells,
1253

Intracerebral tumors
rat 9L model
growth kinetics and treatment response,
MRI study, 643

Intracranial gliomas
gene therapy, MRI and 1H MRS study,
651

Intraductal breast neoplasms
gene alterations pattern, 261

Invasive carcinoma, breast
chromosome 20q13 amplification,
prognostic implications, 1455
flow cytometric DNA analysis, 881

Invasive carcinoma, prostate
prostate-specific antigen facilitation, 1089

Invasive carcinoma, squamous cell
head and neck
predictive and prognostic markers, 1375

Iododeoxyuridine
radiosensitization
5'-aminothyridine and leucovorin
modulation, human colon cancer
cells, 407

Irradiation
cranial, and chemotherapy
delivery and toxicity, rodent model, 731

J

JM216: see Bis-acetato-ammine-
dichlorocyclohexylamine
platinum(IV)

K

Kaposi's sarcoma
AIDS-related
clonality, 257
TGF-β and TGF-β receptors expression,
1119

Kidney carcinoma
MRP expression, 1301

Kinases
cyclic AMP-dependent
topoisorase II inhibitor
hypersensitivity, human breast cells, 49

cyclin-dependent
inhibitor CIP1/WAF1 expression, breast
carcinoma with p53 mutations, 907
modulators
and taxol-induced apoptosis, human
leukemic cells, 1399
polyanion inhibition, 113
thymidine, herpes simplex virus gene
ganciclovir sensitization, ovarian
carcinoma cells, 1571
and MDR1, retroviral coexpression, 447
recombinant adenoviral-mediated
transfer, experimental intracranial
gliomas, 651

K-ras
mutations
and chemotherapy response, colon
cancer, 441
lung cancer, 359

L

Lesions, colorectal
telomerase activity, 1245

Lesions, gastric
telomerase activity, 1245

Letrozole
aromatase inhibition, postmenopausal
breast cancer patients, 1511

Leucovorin
combined with 5-fluorouracil, colon
adenocarcinoma xenografts, 33
iododeoxyuridine radiosensitization
modulation, human colon cancer
cells, 407

Leukemia
apoptosis
high molecular weight DNA fragmentation, 1005
taxol-induced, protein kinase modulators and, 1399
leukemia, 1363
2-chloro-2'-deoxyadenosine pharmacokinetics, 385
elimination by monoclonal antibodies, athymic nude mouse leukemia model, 1179
MOLT-4 cells cycle control, nitrogen mustard, 873
cisplatin, 873
Lipophilic Leukocytes 2-cisplatin, 1399
cytarabine and fludarabine cellular metabolism modulation, 169
WAF1/Cip1 levels, and chemoresistance, 1051
leukemia, acute myelogenous
human M195 cytototoxicity, 63
leukocytes
peripheral blood polyadenosine diphosphoribose) polymerase, 223
LeV damage
immunotoxins targeting vascular toxic syndrome, 1589
Lipophilic cations
rhodamine 123
removing carcinoma cells from bone marrow, 621
Liposome-encapsulated muramyl tripeptide
phosphatidylethanolamine
canine splenic hemangiosarcoma, 1165
combined with cisplatin therapy, canine osteosarcoma, 1595
monocyte cytotoxicity and cytokine response, 493
incorporated annamycin, preclinical toxicity, 1369
Liver CA1 metabolism, 399
metastases colorectal cancer TIMP-1 RNA expression and, 899
sublethal injury and doxorubicin metabolism, 351
Liver cancer autoantibody to DNA topoisomerase II, 417
LMB-1 dosage effect on survival, carcinomatous meningioma rat model, 1545
Lomotrexol with oral folic acid supplement, pharmacokinetics, 1479
Loss of heterozygosity BRCA1, early onset breast and ovarian cancer, 539
chromosome 11q22, epithelial ovarian cancer, 945
chromosome 7q31, prostate cancer, 1385
intraductal breast neoplasms, 261
p16 and p53, head and neck squamous cell carcinoma, 1045
Loss of imprinting IGF-II, prostate, 1471
Lower respiratory tract carcinoma
p53 mutations, 763
Lu-labeled CC49 phase I study, advanced adenocarcinoma, 1447
Lung adenocarcinoma
N',N'-diethylornithospermine efficacy against, preclinical, 847
erhB-2 and p53 oncogene expression, 659
Lung carcinoma
K-ras mutations, 359
non-small cell advanced, TRAIL/FN-α, phase II study, 973
chronic oral etoposide pharmacology, 1517
MRP expression, 1301
p15 and p16 mutations, 687
9p21 homozygous deletions, 687
small cell chronic oral etoposide pharmacology, 1517
lysis, induction by Lys-1-bombesin and mAb 22 immuneconjugate, 425
Lymph node metastases colorectal cancer TIMP-1 RNA expression and, 899
Lymphocytes apoptosis cell cycle control, nitrogen mustard, 873
tumor-infiltrating adaptive immunotherapy, advanced epithelial ovarian cancer, 501
Lymphoid cells
2-chloro-2'-deoxyadenosine resistance, 391
Lymphoma, T-cell anti-idiotypic therapy, immune responses, 1285
Lys-1-bombesin mAb 22 immuneconjugate lysis induction, small cell lung carcinoma, 425
Lysis acute myeloid leukemia cells bispecific antibody 251 × 22, 1319
small cell carcinoma of lung cells Lys-1-bombesin and mAb 22 immuneconjugate induction, 425
M
Magnetic resonance imaging gene therapy of experimental intracranial gliomas, 651
intracerebral rat 9L brain tumors, 643
Magnetic resonance spectroscopy proton gene therapy of experimental intracranial gliomas, 651
Malignancy melanoma mouse anti-idiotypic mAb MK2-23 immunotherapy, 705
peripheral blood leukocytes polyadenosine diphosphoribose) polymerase, 223
superficial tumors thermoradiotherapy, 139
Mammmary epithelial cells cytotoxic effects of adenovirus-mediated wild-type p53 expression, 889
MDM2 mRNA expression, 71
Matrix degradation inhibition by retinoic acid, prostatic carcinoma cells, 755
MCF-7 cells insulin receptor substrate 1 overexpression, 1429
MDM2 amplification, esophageal squamous cell carcinoma, 769
mRNA expression, breast epithelial cells, 71
MDR1 combined with P-glycoprotein overexpression, acute myeloid leukemia, 81
expression, renal cell carcinoma, 1611
doxorubicin mediated, 343
expression, renal cell carcinoma, 1611
and herpes simplex virus thymidine kinase gene retroviral coexpression, 447
transduced cells selective killing by coexpression of MDR1 and herpes simplex virus thymidine kinase gene, 447
Melanoma N',N'-diethylornithospermine efficacy against, preclinical, 847
malignant mouse anti-idiotypic mAb MK2-23 immunotherapy, 705
MRP expression, 1301
MRP expression, 1301
T-cell receptor signal transduction molecule alterations, 1327
T-cell receptor-V chain loss, 1327
Melanoma, ocular OM452 Mullerian inhibiting substance cleavage and antiproliferative effects, 343
Melanoma, uveal cell cycling and prognosis, 41
Meningitis carcinomatous LMB-1 dosage effect on survival, rat model, 11
Messenger RNA bicistronic retrovirus vectors coexpression of MDR1 and herpes simplex virus thymidine kinase gene, 447
**CIP1/WAF1** expression, breast carcinoma
with p53 mutations, 907
clone 4 ER variant expression, and breast cancer, 155
MDM2 expression, breast epithelial cells, 71
multiparametric in situ hybridization analysis
metastasis-related genes, colon carcinoma, 1095

**Metalloproteinase I**
tissue inhibitor
RNA expression, colorectal cancer, and liver metastases, 899

**Metastasis**
breast cancer
advanced, TGF-β1 circulation, 129
pirarubicin combined with 5-fluorouracil and cyclophosphamide, phase II study, 691
rapidly cycled high-dose alkylators, 1267
colon carcinoma
3H-labeled CC49 with deoxypergualin, pilot radioimmunotherapy trial, 1503
liver
colorectal cancer TIMP-1 RNA expression and, 899
prostate cancer
p53 mutations, 1111
related genes multiparametric in situ mRNA hybridization analysis, colon carcinoma, 1095

**Metastatic potential**
epidermal growth factor receptor levels and, human colon carcinoma cells, 19

**Met/HPG receptor gene** overexpression and amplification, colorectal cancer, 147

**Methotrexate**
resistance
antitumor effects of antifolate inhibitors, soft tissue sarcoma cell lines, 631
9-Methoxy-N,N-dimethyl-5-nitropyrazolo[3,4,5-k]acridine-2(6H)-propanamine pharmacokinetics, mice, 831
phase I clinical trial, 1487

**Microdissection**
chromosome
DNA sequence amplification identified by, prostate cancer, prognostic implications, 11

**MK2–23**
mouse anti-idiotypic mAb, malignant melanoma immunotherapy, 705

**MOLT-4 cells**
apoptosis
cell cycle control, nitrogen mustard, 873

**Monoclonal antibody**
anti-CD3 combined with interleukin 2, therapy, 481
anti-CD3 (humanized mAb M195)
cytotoxicity, myelogenous leukemia, 63
anti-CD15 (PM-81)
sorotherapy, acute myeloid leukemia, 965
anti-EGFR chimerized with IgG1, biological efficacy, human tumor xenograft model, 1311
tumor cell growth inhibition, 161
anti-FcγRI (mAb 22)
Lys3-bombesin immunonjugate, lysis induction, small cell lung carcinoma, 425
CC49 1H-labeled, and deoxypergualin, metastatic colon carcinoma, 1503
1H-Lu-labeled, advanced adenocarcinoma, 1447

**DF3-P**
epitope expression, human ovarian carcinomas, 565
E48
biodistribution, head and neck cancer, 277
leukemia elimination, athymic nude mouse leukemia model, 1179
MK2–23 immunotherapy, malignant melanoma, 705
U36 tumor targeting, head and neck cancer, 591

**Monocytes**
cytotoxicity, multimellar vesicle muramyl tripeptide phosphatidylethanolamine treatment, 493
mediated lysis
acute myeloid leukemia cells, bispecific antibody 251 × 22, 1319
small cell carcinoma of lung cells, Lys3-bombesin and mAb 22 immunonjugate induction, 425

**MRP**
expression, human cancers, 1301
overexpression, acute myeloid leukemia, 81

**Müllerian inhibiting substance**
cleavage and antiproiferative effects, 343

**Multidrug resistance**
functional phenotype, acute myeloid leukemia, 81
gene expression, renal cell carcinoma, 1611
HSV-TK retroviral coexpression, 447
P-glycoprotein phosphorylation byrostatin 1 and, breast cancer cells, 1581

**Multimellar vesicle muramyl tripeptide phosphatidylethanolamine therapy**
monocyte cytotoxicity and cytokine response, 493

**Muramyl tripeptide phosphatidylethanolamine**
liposome-encapsulated
canine splenic hemangiosarcoma, 1165
combined with cisplatin therapy, canine osteosarcoma, 1595
murine cytotoxicity and cytokine response, 493

**Murine Double Minute 2:**  see **MDM2**

**Murine monoclonal antibody CC49**
immune response
deoxypergualin modulation, metastatic colon carcinoma, 1503
1H-Lu-labeled, advanced adenocarcinoma, 1447

**Mutations**
epidermal growth factor receptor, immunotoxins, 859
germline
BRCA1, early onset breast and ovarian cancer, 539
H-ras, lung cancer, 539
K-ras and chemotherapy response, colon cancer, 441
lung cancer, 359
p16, head and neck squamous cell carcinoma, 1043

**p53**
brust carcinoma **CIP1/WAF1** expression, 907
esophageal squamous cell carcinoma, 769
head and neck squamous cell carcinoma, 1043
metastatic prostate cancer, 1111
and tamoxifen resistance, breast cancer, 1203
upper and lower respiratory tract carcinoma, 763

**Myeloma**
P-glycoprotein chemosensitization, SCID human xenograft model, 1563

---

**N**

**National Cancer Institute Workshop**
proceedings, tumor receptor imaging, 921

**Natural killer cells**
activated
stem cell transplantation and immunotherapy, immediate posttransplant, 607

**Neoplasms:** see also **Tumors**
CD44 splice variants expression, cervical epithelium, 1125
gene alterations pattern, intraductal breast, 261
telomerase activity, gastric and colorectal lesions, 1245

**Neutrophils**
mediated lysis
Lys3-bombesin and mAb 22 immunonjugate induction, small cell lung carcinoma, 425

**Nitrogen mustard**
apoptosis cell cycle control, 873

**Non-small cell lung cancer**
advanced
TRAF1N-α, phase II study, 973
chromosome 9p21 homozygous deletions, 687
chronic oral etoposide pharmacology, 1517
MRP expression, 1301
p15 and p16 mutations, 687

**Norsegoline**
anti-leukemic effects, 823
NSC 366140:  see 9-Methoxy-N,N-dimethyl-5-nitropyrazolo[3,4,5-k]acridine-2(6H)-propanamine
NSC 609974:  see CAI

**Nuclear protein**
p53
expression, prostate cancer, 1295

**Nucleoside analogue**
induced apoptosis
Osteosarcoma

Ornithine

Oncotoxins

Oncogenes: see also Genes; Proto-oncogenes

c-erb-B2 amplification prognostic value, bladder carcinoma, 1189
c-jun induction, and apoptosis, human acute leukemia cells, 559
c-met overexpression and amplification, colorectal cancer, 147
erbB-3 expression, lung adenocarcinoma, 659
H-ras mutations, lung cancer, 359
K-ras mutations, and chemotherapy response, colon cancer, 441
mutations, lung cancer, 359
p53 expression, lung adenocarcinoma, 659
Oncoprotein: see also Protein

bcl-2 expression, and node-positive breast cancer outcome, 199
expression, stage II colon carcinoma, 1103
expression, VP-16-resistant cells, 1391
Oncotoxins

TNP superficial bladder cancer, phase I clinical study, 57

Ornithine decarboxylase

levels, colorectal carcinoma, 665

Osteosarcoma

liposome-encapsulated muramyll tripeptide phosphatidylethanolamine and cisplatin therapy, dogs, 1595

Ovarian carcinoma

activating factor, characterization, 1223
advanced
dose intensity, 575
advanced epithelial
tumor-infiltrating lymphocyte adoptive immunotherapy, 501
autocrine endothelin-1 growth factor effects, 1059
CD44 heterogeneity, 333
cisplatin and JM216 transport, 981

DF3-P expression, 565
N,N'-diethylthiophosphoramide efficacy against, preclinical, 847
early onset germline BRCA1 mutations and loss of heterozygosity, 539
epithelial progesterone receptor content, 11q22
loss of heterozygosity and, 945
ganciclovir sensitization, HSV-TK gene, 1571
HSP27 expression, 1603
MRP expression, 1301

P

p15 mutations, non-small cell lung cancers, 687
p16 loss of heterozygosity, head and neck squamous cell carcinoma, 1043
mutations head and neck squamous cell carcinoma, 1043
non-small cell lung cancers, 687
p53 expression cell cycle control, nitrogen mustard, 873
lung adenocarcinoma, 659
loss of heterozygosity, head and neck squamous cell carcinoma, 1043
mutations breast carcinoma CIP1/WAF1 expression, 907
esophageal squamous cell carcinoma, 769
head and neck squamous cell carcinoma, 1043
metastatic prostate cancer, 1111
and tamoxifen resistance, breast cancer, 1203
upper and lower respiratory tract carcinoma, 763
p53 protein antibodies, various cancer types, 1463
autotoxins, glioma, 775
expression pretreatment, and end-stage squamous cell carcinoma of head and neck, 1407
VP-16-resistant cells, 1391
nuclear expression, prostate cancer, 1295
wild-type adenovirus-mediated expression, cytotoxic effects, mammary epithelial cells, 889
Paclitaxel breast cancer therapy, 247
pharmacokinetics and pharmacodynamics, 3-hour infusion versus 24-hour infusion, 599
Pancreatic cancer

erbB-3 expression, 1413
Papillary renal cell carcinoma

EGF-R and TGF-α expression, 913
PAX5 expression, astrocytomas, 207
p26BCL-2 human leukemic cells
taxol-induced apoptosis, protein kinase modulators and, 1399
PD115934 pharmacokinetics, mice, 831
phase I clinical trial, 1487
Pentoxifylline
combined with thiotePA dose escalation, advanced breast cancer, 791
PE38QQR C242Flab)- recombinant anti-colorectal cancer immunotoxin, 1015
h13-human glioma sensitivity, 1253
Peripheral blood

leukocytes

poly(adenoamine diphosphoribose) polymerase, 223
progenitor cells
filgrastim-mobilized, adjuvant treatment, breast cancer, 715
rapidly cycled high-dose alkylators supported by, metastatic breast cancer, 1267
stem cells
autologous transplantation and immunotherapy, immediate posttransplant, 807
P-glycoprotein

chemosensitization, SCID human myeloma xenograft model, 1563
combined with MDR1 overexpression, acute myeloid leukemia, 81
phosphorylation
bryostatin 1 and, breast cancer cells, 1581
Phenyto lactate

chemoprevention, 865
Phosphatidylethanolamine

liposome-encapsulated muramyl tripeptide canine splenic hemangiosarcoma, 1165
combined with cisplatin therapy, canine osteosarcoma, 1595
monocyte cytotoxicity and cytokine response, 493
Phosphorylation

P-glycoprotein

bryostatin 1 and, breast cancer cells, 1581
Pirarubicin

combined with 5-fluorouracil and cyclophosphamide, metastatic breast cancer, 691
Plasma

TGF-β1 circulation, normal human, 129
Plasma membrane protein
cisplatin resistance, ovarian carcinoma cell lines, 981
Plasminogen activator

urokinase-type receptor, prognostic significance, breast cancer, 1079
retinoic acid modulation, DU-145 cells, 747
Platelet-derived endothelial cell growth factor

expression, breast cancer, 961
Platinum
dose intensity, advanced ovarian cancer, 575

PM-81
serotherapy, acute myeloid leukemia, 965

PML/RARs
fusion protein, acute promyelocytic leukemia, 583

Poly(adenosine diphosphoribose) polynucleotide
peripheral blood leukocytes, 223

Polyamine analogues
N,N,N,N',diethylnorspermine
antitumor efficacy, preclinical, 847

Polyanions
protein kinase C inhibition, 113

Preneoplasia
gastric and colorectal lesions
telomerase activity, 1245

Prodrugs
5-fluorouracil, colorectal cancer therapy, 839

Progenitor cells
peripheral blood filgrastim-mobilized, breast cancer, 715
rapidly cycled high-dose alkylators supported by, metastatic breast cancer, 1267

Progesterone
receptor
11q22 loss of heterozygosity and, epithelial ovarian cancer, 945

Prostate
loss of imprinting, IGF-II, 1471

Prostate-specific antigen
human prostate cancer cell invasion facilitation, 1089

Prostatic carcinoma
cell invasion
prostate-specific antigen facilitation, 1089

cell kinetic changes, human, 473
chromosome 7q31 loss of heterozygosity, 1385
DNA sequence amplification identified by chromosome microdissection, prognostic implications, 11

DU-145 cells
urokinase-type plasminogen activator, retinoic acid modulation, 747
matrix degradation inhibition by retinoic acid, 755
metastatic
p53 mutations, 1111

MMP expression, 1301
p53 nuclear protein expression, prognostic marker, 1295
progression
EGF-R and TGF-α expression, 545
vitamin D receptor expression, 24-hydroxylase activity, and 1α,25-dihydroxyvitamin D3 growth inhibition, 997

Protein: see also Oncoprotein
chimeric
C242Fab′-PE38QQR, recombinant anti-colorectal cancer immunotoxin, 1015
hIL-13-PE38QQR, human glioma sensitivity, 1253
differentiation and retinoylation
enhancement by N-(4-hydroxyphenyl)retinamide combined with retinoic acid, 637
expression, breast epithelial cells, 71
fusion
PML/RARa, acute promyelocytic leukemia, 583
p53 antibodies, various cancer types, 1463
autotubulins, glioma, 775
expression, VP-16-resistant cells, 1391
immunoreactivity, glioma, 1617
nuclear expression, prostate cancer, 1295
pretreatment expression, and end-stage squamous cell carcinoma of head and neck, 1407
wild-type, adenovirus-mediated expression, cytotoxic effects, mammatory epithelial cells, 889
ras antibody, colon cancer, 1071
WAF1/Cip1 levels and chemoresistance, acute myelogenous leukemia, 1051

Protein kinase
modulators
and taxol-induced apoptosis, human leukemic cells, 1399

Protein kinase C
polynucleotide, 113

Protein kinase type 1
cyclic AMP-dependent topoisomerase II inhibitor
hypersensitivity, human breast cells, 49

Proton magnetic resonance spectroscopy
gene therapy of experimental intracranial gliomas, 651

Proto-oncogenes
c-myc
posttranscriptional regulation, ER′ breast cancer cells, 235

Pseudomonas exotoxin
Fab′-C242- recombinant anti-colorectal cancer immunotoxin, 1015
human IL-13- human glioma sensitivity, 1253
immunotoxins containing
-mediated vascular leak syndrome, 1589

Purine
folate-based inhibitors
antitumor effects, soft tissue sarcoma cell lines, 631

Pyrazolocarboxamide
pharmacokinetics, mice, 831
Pyrazolocarboxamide NSC366140
phase I clinical trial, 1487

PZA: see Pyrazolocarboxamide

Radioimmunotherapy
hematology oncology
problems and progress, 1439
31P-labeled CC49 with doxoyrperuglauin pilot trial, metastatic colon carcinoma, 1503

Radioimmunotherapy
iododeoxyuridine
5'-aminothymidine and leucovorin modulation, human colon cancer cells, 407

Radiotherapy
fractionated fibroblast response, 785
ras antibody, colon cancer, 1071
ras and chemotherapy response, colon cancer, 441

Rat 9L brain tumour model
growth kinetics and treatment response, MRI study, 643

Receptors
colony-stimulating factor 1
and etiopathogenesis of endometrial adenocarcinoma, 313
epidermal growth factor
4,5-bis(4-fluorooanilino)phthalimide inhibitor, in vivo antitumor effects, 813
chimeric antibody to, biological efficacy, human tumor xenograft model, 1311
ectodomain, squamous cell carcinoma, 551
expression, and metastatic potential, human colon carcinoma cells, 19
expression, prostate neoplasms, 545
expression, renal cell carcinoma, 913
mAb 528 against, tumor cell growth inhibition, 161
mutant, immunotoxins that target, 859
estrogen
clon 4 variant mRNA expression, and breast cancer, 155
-positive breast cancer cells, c-myc posttranscriptional regulation, 235
hepatocyte growth factor
Met gene overexpression and amplification, colorectal cancer, 147
insulin, substrate 1
overexpression, breast cancer, 1429
interleukin-13
overexpression, human glioma cells, 1253
progesterone
11q22 loss of heterozygosity and, epithelial ovarian cancer, 945
retinoic acid, α
PML fusion protein, acute promyelocytic leukemia, 583
T-cell
signal transduction molecule alterations, melanoma, 1327
T-cell, ζ chain
loss, melanoma, 1327
transferrin
murine immunoglobulin A antibody 426 against, phase Ia trial, 1259
transforming growth factor β
expression, AIDS-associated Kaposi’s sarcoma, 1119

Retrovirus

Retinoic acid

Rhodamine 123

removing carcinoma cells from bone marrow, 621

RNA

TIMP-1 expression, colorectal cancer and liver metastases, 899

RNase L

elevated levels, colorectal tumorigenesis, 1421

Saliva

chemopreventive enzymes, induction, 1153

Sarcoma, Kaposi’s

AIDS-related clonality, 257

TGF-β and TGF-β receptors expression, 1119

Sarcoma, soft tissue

antitumor effects of antifolate inhibitors, 631

MRP expression, 1301

SCID: see Severe combined immunodeficiency

Sensitivity: see also Hypersensitivity

1-β-D-arabinofuranosylcytosine, acute myeloid leukemia, 81

hiL-13-PE38QQR, human glioma cells, 1253

Serine proteases

prostate-specific antigen human prostate cancer cell invasion facilitation, 1089

Serotherapy

IgM mAb PM-81, acute myeloid leukemia, 965

Serum

hepatoocyte growth factor concentrations, breast cancer, 1031

p53 autantibodies, glioma, 775

Severe combined immunodeficiency

P-glycoprotein chemosensitization, human myeloma xenograft model, 1563

Skin fibroblasts

response to fractionated radiation, 785

Small cell carcinoma, lung

chronic oral etoposide pharmacology, 1517

lysis

Lys1-bombesin and mAb 22

immunoconjugate induction, 425

Soft tissue sarcoma

antitumor effects of antifolate inhibitors, 631

MRP expression, 1301

Solid tumors

N,N'-diethylnorspermine efficacy against, preclinical, 847

drug-resistant chemotherapy combined with CsA and bone marrow transplant, phase I clinical trial, 1495

dendolin up-regulation, vascular endothelial cells, 1623

Southwest Oncology Group Study

recombinant IL-3 phase I trial, 1139

Splenic hemangiosarcoma

liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy, canine, 1165

Squamous cell carcinoma

EGF-R ectodomain, 551

radiation-induced proliferation with EGF, 1557

Squamous cell carcinoma, esophageal

MRP expression, 1301

p53 mutations, MDM2 amplification, and HPV infection, 769

Squamous cell carcinoma, head and neck

cell kinetics, 527

dend-stage pretreatment p53 expression and, 1407

GM-CSF-secreting CD34+ cells, 95

mAb E48 biodistribution, 277

p16 and p53 loss of heterozygosity and mutations, 1043

predictive and prognostic markers, 1375

tumor targeting mAb U36, 591

Squamous cell carcinoma, lung

K-ras mutations, 359

Stem cells

autologous peripheral blood transplantation and immunotherapy, 537

immediate posttransplant, 1285

Superficial bladder cancer

toxotinin TP40, phase I clinical study, 57

tumor-associated antigens, prognostic factors, 1195

Superficial malignant tumors

thermoroadiotherapy, 139

Suramin

cellular pharmacology, 509

related polyanions

protein kinase C inhibition, 113

Swainsonine

antitumor effects, 935

T

cells

antigen highly restricted, anti-idiotype antibody mimicking, T-cell lymphoma therapy, 1285

lymphoma

anti-idiotype therapy, immune responses, 1285

receptor

signal transduction molecule alterations, melanoma, 1327

receptor-α chain loss, melanoma, 1327

TAL1

rearrangements, adult acute lymphoblastic leukemia, Cancer and Leukemia Group B study, 459

Tamoxifen

advanced breast cancer therapy
doxorubicin efficacy and tolerability, phase II study, 287

doxorubicin and, 467

resistance

p53 mutations and, breast cancer, 1203

Taxol

-induced apoptosis
protein kinase modulators and, human leukemic cells, 1399

**Technetium-99m**
- labeled mAb U36
tumor targeting, head and neck cancer, 591

**Telomerase**
activity, gastric and colorectal lesions, 1245

**Tenascin**
expression, human breast cancer, 1035

**Testis carcinoma**
MRP expression, 1301

**TF-1 cells**
growth factor-induced apoptosis prevention by PML/RARα, acute promyelocytic leukemia, 583

**TGF: see Transforming growth factor**

**Thermal radiotherapy**
of superficial malignant tumors, 139

**ThioTEPA**
combined with pentoxifylline
dose escalation, advanced breast cancer, 791

**Thymidine-5'-triphosphate**
2'-deoxyadenosine-5'-triphosphate ratio and thymidine death, colon carcinoma cells, 723

**Thymidylate**
antifolate inhibitors
AG337, 24-hour study, 1275
antitumor effects, human soft tissue sarcoma cell lines, 631

**Thymineless death**
2'-deoxyadenosine-5'-triphosphate/thymidine-5'-triphosphate and, colon carcinoma cells, 723

**TIMP-1: see Tissue inhibitor of metalloproteinase 1**

**Tissue inhibitor of metalloproteinase 1**
RNA expression, colorectal cancer and liver metastases, 899

**Tolerability**
vorozole, advanced breast cancer, 287

**Toxicity**
cranial irradiation and chemotherapy, rodent model, 731
ganciclovir
gene therapy, MRI and 1H MRS study, 651
liposomal amannycin, preclinical, 1369

**Toxins: see Immunotoxins; Oncotoxins**

**TP40**
superficial bladder cancer, phase I clinical study, 57

**TRA: see trans-Retinoic acid**

**Transferrin**
receptor
murine immunoglobulin A antibody 42/6 against, phase Ia trial, 1259

**Transforming growth factor-α**
expression
prostatic neoplasms, 545
renal cell carcinoma, 913

**Transforming growth factor-β**
expression, AIDS-associated Kaposi’s sarcoma, 1119

**Transforming growth factor-β1**
circulation, advanced metastatic breast cancer and normal human plasma, 129

**Transitional cell carcinoma, bladder**
human papillomavirus, 435
tumor-associated antigens, prognostic factors, 1195

**Transplantation, bone marrow**
combined with chemotherapy and CsA, phase I clinical trial, 1495

**Transplantation, stem cell**
and immunotherapy, immediate posttransplant, 607

**N,N',N''-Triethylenethiophosphoramide**
combined with pentoxifylline
dose escalation, advanced breast cancer, 791

**Tumor cell growth**
inhibition by 8-chloro-cyclic AMP and anti-EGFR mAb, 161
proliferative rate, head and neck cancers, 527

**Tumor progression**
EGF-R and TGF-α expression, prostatic, 545
erbB-3 expression and, pancreatic cancer, 1413

**Tumor targeting**
mAb U36, head and neck cancer, 591

**Tumorigenesis, colorectal**
elevated RNase L levels, 1421

**Tumor-infiltrating lymphocytes**
adoptive immunotherapy, advanced epithelial ovarian cancer, 501

**Tumors: see also Neoplasms; specific tumors**
-associated antigens
prognostic factors, transitional cell bladder carcinoma, 1195
4.5-bis(4-fluoroanilino)phthalimide effects against, 813
carbohydrate processing inhibitor effects against, 935
cytotoxic effects of adenosine-mediated wild-type p53 expression, mammary epithelial cells, 889
N,N,N''-diethylnorspermine efficacy against, preclinical, 847
estrogen growth and transformation requirements, MCF-7 cells, 1429
killing
cyclophosphamide/P450 2B1 gene therapy, 1171
progesterone receptor content
11q22 loss of heterozygosity and,
epithelial ovarian cancer, 945
receptors
imaging, Workshop Report, 921
superficial malignant thermadiotherapy, 139
xenograft
biological efficacy of chimeric antibody to EGFR, human model, 1311

**Tumors, brain**
intracerebral rat 9L model
growth kinetics and treatment response,
MRI study, 643
intracranial gliomas
gene therapy, MRI and 1H MRS study, 651
VP-16-resistant cells
Topoisomerase II, Bcl-2, and p53 expression, 1391

**Tumors, solid**
drug-resistant chemotherapy combined with CsA and bone marrow transplant, phase I clinical trial, 1495
dedoglin up-regulation, vascular endothelial cells, 1623

**U**
U36
tumor targeting, head and neck cancer, 591

**Upper respiratory tract carcinoma**
p53 mutations, 763

**Urinary bladder: see Bladder**

**Urinary carcinoma**
EFG-R ectodomain, squamous cell carcinoma, 551

**Urokinase**
-mediated matrix degradation, prostatic carcinoma cells, 755
-type plasminogen activator
retinoic acid modulation, DU-145 cells, 747
-type plasminogen activator receptor
growth factor-31
expression, 1079

**Uterine cervical carcinoma**
hHL-6-induced cachexia, human xenograft, 1353
HSP70 levels, 1217

**Uterine cervix**
epithelium
CD44 splice variants expression, 1125
HSP70 expression, 1217

**Uveal melanoma**
prognosis, cell cycling and, 41

**V**

**Vascular endothelial cells**
dedoglin up-regulation, human solid tumors, 1623

**Vascular endothelial growth factor**
expression, breast cancer, 961

**Vascular leak syndrome**
immunotoxin-mediated, 1589

**Vitamin D**
receptor expression, prostatic carcinoma cell lines, 997

**Vorozole**
advanced breast cancer therapy, phase II study, 287

**VP-16: see Etoposide**

**W**

**WAFI/Cip1**
levels and chemoresistance, acute myelogenous leukemia, 1051

**Wild-type allele**
loss of Brca1, early breast and ovarian cancer, 539

**Wild-type p53**
adeno virus-mediated expression
cytotoxic effects, mammary epithelial cells, 889

Wilms' tumor
bFGF levels, 327

Withdrawal
growth factor
-induced apoptosis, prevention by PML/RARα, acute promyelocytic leukemia, 583

Wnt5
cloning, expression, and up-regulation, human breast cancers, 215

X

Xenografts
colon adenocarcinoma
FURA-leucovorin activity, 33
colorectal tumor
recombinant C242F(ab')2-PE38QQR
immunotoxin, 1015
human carcinoma
B1(Fv)PE38 and B1(dsFv)PE38

immunotoxin characterizations, nude mice, 1023
human tumor model
biological efficacy of chimeric antibody to EGFR, 1311
human uterine cervical carcinoma
hIL-6-induced cachexia, 1353
SCID human myeloma model
P-glycoprotein chemosensitization, 1563
Instructions for Authors

Scope

Clinical Cancer Research, a new journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

Specific areas of interest include clinical and translational research in: molecular pharmacology and chemotherapy; drug sensitivity and resistance; tumor immunology and immunotherapy; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; pathology, markers, and prognostic indicators; growth factors, cytokines, and signal transduction; bone marrow transplantation; gene therapy; cancer endocrinology; cell adhesion, invasion, and metastasis; prevention of primary and recurrent cancer; differentiation and cell death; clinical genetics; and detection of minimal disease.

Editorial Policy

When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled.

Journal policy requires that authors, reviewers, and Associate Editors reveal in a letter to the Editor-in-Chief any relationships that they have that could be construed as causing a conflict of interest with regard to a manuscript under review. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.

Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the copyright owner of the journal, prior to publication. The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. A copy of the Declaration is available from the American Medical Association, P.O. Box 7046, Dover, DE 19903-7046. For animal experimentation reported in the journal, it is expected that investigators will have observed the Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education issued by the New York Academy of Sciences’ Ad Hoc Committee on Animal Research, a copy of which is available for $5.00 from the Marketing Department, New York Academy of Sciences, 2 East 63rd Street, New York, NY 10021-7289. All human and animal studies must have been approved by the investigator’s Institutional Review Board.

Review Process

The review process, expedited by fax transmission and overnight mail service, is conducted as rapidly as possible. Each submitted manuscript is reviewed by at least two experts in the field of investigation. If the authors are invited to submit a revised manuscript for an expedited further review, the revised version must be submitted within three months.

Manuscript Submission

Send manuscripts to John Mendelsohn, M.D., Editor-in-Chief, Clinical Cancer Research, at Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Submit four original sets (not photocopies) of figures along with four copies of the manuscript. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission.

Advances in Brief will be reserved for concise, definitive reports of novel observations and discoveries that have unusual importance. A request for consideration for Advances in Brief should be included in the letter of submission. A Minireview is a brief analysis (typically 3-4 printed pages) of a focused, timely research topic, aimed at a multidisciplinary audience. Minireviews and Controversies in Clinical Cancer Research that are submitted or solicited will undergo editorial review. The Editors welcome Letters to the Editor, which will be published if they are determined to be appropriate.

The letter of submission should suggest the Associate Editor (or Editor-in-Chief) who will serve as primary reviewer of the manuscript. In addition, we invite authors to provide the names, addresses, and telephone/fax numbers of up to five potential reviewers who are not current or recent collaborators or advisors in the area under investigation.

For both original and revised submissions, we cannot guarantee that manuscripts and illustrations will be returned to the author.

Format

Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 x 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:

1. Title page, including title, authors and their institutions, research support, and address plus telephone/fax numbers of the corresponding author;
2. A running title of fewer than 50 characters;
3. Three to five key words that do not appear in the title;
4. Abstract, of not more than 250 words, stating briefly the objectives, methods, results, and conclusions of the study;
5. Text arranged in this order: Introduction, Methods, Results, Discussion, Acknowledgments, References;
6. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;
7. Tables, on pages separate from the text, with descriptive titles and legends that make the data understandable without reference to the text;
8. Figure legends, on pages separate from the text, with descriptive titles and explanations to make the data understandable without reference to the text. Define all symbols and include staining for half tones where applicable;

References
Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission. Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced.

SAMPLE REFERENCES:

Figures
Provide four original sets of figures (whether line-cut drawings or halftones). Each sorted set should be in a separate labeled envelope, for distribution to reviewers. A typed label placed on the reverse side of each figure should contain the first author’s name, figure number, and an arrow indicating top of figure. Letters and numbers on figures should not be larger than 12-point type. All figures will be published at a width of approximately 3 inches (8 cm) unless the author requests a greater width. Use tissue overlays to indicate important areas of the photographs that must be reproduced with greater fidelity.
Authors are encouraged to submit color figures. The expense of reproducing color photographs will be charged to the authors. Submit color figures on flexible backing.

Typesetting Manuscripts from Computer Disks
Clinical Cancer Research welcomes disks to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding disk submission. It is the author’s responsibility to ensure that the material on the disk matches the final accepted version of the manuscript.

For more information, contact:
John Mendelsohn, M.D., Editor-in-Chief. Clinical Cancer Research, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Telephone 212-639-6317, Fax 212-717-3629 or:
AMERICAN ASSOCIATION FOR CANCER RESEARCH
GUIDELINES FOR APPLICATION FOR ACTIVE AND CORRESPONDING MEMBERSHIP

BENEFITS OF MEMBERSHIP
The American Association for Cancer Research (AACR), a scientific society of over 10,000 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:
1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. an advance copy of the Program and Proceedings of the American Association for Cancer Research pertaining to each annual meeting;
3. reduced registration rates at annual meetings;
4. priority notice of small, focussed meetings in the AACR's exciting series of Special Conferences in Cancer Research;
5. reduced registration rates for Special Conferences;
6. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
7. receipt of AACR Newsletters and other important announce-
ments;
8. early notification of and reduced rates for participation in the AACR Employment Register;
9. an up-to-date Membership Directory of thousands of researchers in the cancer field;
10. the professional benefits of AACR's public education activities concerning funding for cancer research and press coverage of the latest research findings;
11. participation in Summer Workshops that foster networking opportunities and science education for young investigators; and
12. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP
Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for associate membership. Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION
There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

<table>
<thead>
<tr>
<th>Receipt of Application in AACR Office</th>
<th>Notification of Candidate</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 1</td>
<td>March</td>
</tr>
<tr>
<td>May 1</td>
<td>July</td>
</tr>
<tr>
<td>September 1</td>
<td>November</td>
</tr>
</tbody>
</table>

A complete application consists of the following material:
1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate's most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate's achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. -OR- The nominator may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a secondor who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). -OR- The secondor may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address shown below. Questions regarding procedures for membership application may also be directed to the following address:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215-440-9300
FAX: 215-440-9313

RESPONSIBILITIES OF MEMBERSHIP
Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1996 annual dues for active members are $160, $95 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year's membership dues are paid in full.

Corresponding members are required to pay dues ($80 in 1996) and may, if they wish, subscribe to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at reduced member rates.

Applicants elected in March will be responsible for payment of that year's dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Futi, Ph.D.
Executive Director
APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

NAME OF CANDIDATE: ___________________________________________  DATE OF BIRTH: ____________

LAST     FIRST     M.I.

PRESENT POSITION/TITLE: __________________________________________

INSTITUTIONAL AFFILIATION: ________________________________________

INSTITUTIONAL ADDRESS: __________________________________________

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: ____________________________  E-MAIL NUMBER (CARRIER): ______________________

FAX NUMBER: ____________________________  PRIMARY FIELD OF RESEARCH (Please check only one):

___ Biochemistry and Biophysics  ___ Biostatistics  ___ Carcinogenesis
___ Cellular Biology and Genetics  ___ Clinical Investigations  ___ Endocrinology
___ Epidemiology  ___ Immunology  ___ Molecular Biology and Genetics
___ Preclinical Pharmacology and Experimental Therapeutics  ___ Virology  ___ Other: ____________________________

(Please specify)

ACADEMIC DEGREES (Including where and when granted)

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded.)

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

CANDIDATE NOMINATED BY*: ____________________________________________  CANDIDATE SECONDED BY*: ____________________________

(Please print)  (Please print)

CANDIDATE IS APPLYING FOR (Check one):  ☐ ACTIVE  ☐ CORRESPONDING  ☐ MEMBERSHIP

STATEMENT OF SUPPORT

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

How long has the candidate worked in the field of cancer research? ________ years

Will the candidate make a long-term contribution to cancer research? Yes ____ No ____

Does the candidate's research adhere to accepted ethical standards? Yes ____ No ____

I therefore recommend this candidate for membership in the American Association for Cancer Research.

________________________________________________________________________

Signature of nominator*  Date

________________________________________________________________________

Signature of seconder*  Date

See Guidelines for Application on the reverse side of this form for further instructions.
*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR.

(This form may be reproduced.)
QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a paper for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege.);
2. an advance copy of the scientific Program and (if one has been purchased by the associate member) the Proceedings of the American Association for Cancer Research which contains abstracts of all papers being presented at each annual meeting;
3. the privilege of registering for the annual meeting at the low student rate (This rate is otherwise available only to predoctoral students.);
4. preferred access to the AACR Employment Register;
5. optional subscriptions to the Association’s high-quality journals Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates;
6. priority notification of events in the AACR’s series of special conferences on timely subjects in the field;
7. reduced registration rates at special conferences;
8. the receipt of AACR newsletters, meeting announcements, and an up-to-date membership directory; and
9. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate and the nominator. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year's dues payment must accompany the application. Dues are currently $35 for associate members residing in the Americas and $45 for residents of other countries. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the $35 or $45 dues payment to:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
215/440-9300

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1995 and 1996 have been set at $35 per year for residents of the Americas and $45 for residents of other countries. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in November 1995 for the forthcoming annual meeting must have paid dues for 1995. Any newly elected associate members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member’s subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member’s current registrar, dean, or department head, verifying the member's current academic status. The Association's By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1995 may retain associate membership until December 31, 1999. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D.
Executive Director
APPLICATION FOR ASSOCIATE MEMBERSHIP

NAME OF CANDIDATE: ____________________________________________ DATE OF BIRTH: __________

INSTITUTIONAL AFFILIATION: ____________________________________________

INSTITUTIONAL ADDRESS: ____________________________________________

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: ______________________ FAX NUMBER: ______________________

PRESENT ACADEMIC STATUS/TITLE (Please check only one): __________

Graduate Student __________ Medical Student

Physician in Training __________ Postdoctoral Fellow

PRIMARY FIELD OF RESEARCH (Please check only one):

____ Biochemistry and Biophysics ______ Biostatistics ______ Carcinogenesis

____ Cellular Biology and Genetics ______ Clinical Investigations ______ Endocrinology

____ Epidemiology ______ Immunology ______ Molecular Biology and Genetics

____ Preclinical Pharmacology and Experimental Therapeutics ______ Virology ______ Other: ______________________

(Please specify)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

CANDIDATE NOMINATED BY: ____________________________ (Please type or print name of AACR active member* in good standing.)

SIGNATURES

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.

Signature of Candidate: ____________________________________________ Date: __________

I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator*: ____________________________________________ Date: __________

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year’s dues. Dues are currently $35 for associate members residing in the Americas and $45 for residents of other countries.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:

☐ The enclosed dues payment should be applied to the current ☐ forthcoming calendar year.

(Note: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor an abstract for presentation at the annual meeting in March or April of that year.) See Guidelines for Application on the reverse side of this form for further instructions.

*Nominator must be active, corresponding, emeritus, or honorary member of the AACR.

(This form may be reproduced.)
**ADVANCE REGISTRATION FORM**

**AMERICAN ASSOCIATION FOR CANCER RESEARCH**  
**87TH ANNUAL MEETING - WASHINGTON, DC - APRIL 20-24, 1996**

Return to  
American Association for Cancer Research • Public Ledger Building, Suite 816  
150 S. Independence Mall West • Philadelphia, PA 19106-3483 • FAX: 215-440-7228

**DEADLINES:**  
- March 1, 1996 for reduced rates and to ensure receipt of meeting materials by mail in late March or early April  
- March 25, 1996 for all registration by mail (Registration forms received after this date will not be accepted. Registration will be conducted at the Washington Convention Center from April 20-24.)  
- April 17, 1996 to cancel registration and receive refund less cancellation fee ($35)

(Please print)

**NAME:**  
______________________________  
______________________________  
______________________________

**ADDRESS:**  
First/Middle Initial  
AACR Member Number

Street, Building, or Post Office Box

City  
State or Province  
Zip/Postal Code  
Country (if not U.S.)

**TELEPHONE NO.:**  
FAX NO.: 

☐ Check this box if you have a physical disability and have special requirements for transportation, hotel accommodations, or other facilities in connection with the meeting. A member of the Association Staff will contact you.

**WHAT IS YOUR PRIMARY FIELD OF RESEARCH** (Please check only one):

- ☐ Biochemistry and Biophysics  
- ☐ Carcinogenesis  
- ☐ Cellular Biology & Genetics  
- ☐ Clinical Investigations  
- ☐ Endocrinology  
- ☐ Epidemiology  
- ☐ Experimental Therapeutics  
- ☐ Immunology  
- ☐ Molecular Biology & Genetics  
- ☐ Prevention  
- ☐ Radiobiology/Radiation Oncology  
- ☐ Virology  
- ☐ Other (please specify): ________________________________

**ARE YOU THE PRESENTER OF AN ABSTRACT SUBMITTED FOR THE 1996 AACR MEETING?**  
☐ Yes ☐ No

**ON WHICH DAYS WILL YOU ATTEND THE 1996 AACR ANNUAL MEETING?**  
☐ Saturday, April 20 ☐ Sunday, April 21 ☐ Monday, April 22 ☐ Tuesday, April 23 ☐ Wednesday, April 24

**PAYMENT OF REGISTRATION**

Fees may be paid by check or with a MasterCard, VISA, American Express, or Eurocard account. All payments must be made in U.S. currency, and all checks must be drawn on a U.S. bank. Payment must accompany this form; purchase orders will not be accepted as payment.

<table>
<thead>
<tr>
<th></th>
<th>On or Before March 1</th>
<th>After March 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active/Corresponding Member Rate</td>
<td>$135</td>
<td>$170</td>
</tr>
<tr>
<td>Nonmember Rate</td>
<td>$270</td>
<td>$340</td>
</tr>
<tr>
<td>Emeritus Member Rate</td>
<td>$50</td>
<td>$50</td>
</tr>
<tr>
<td>Associate Member Rate</td>
<td>$75</td>
<td>$85</td>
</tr>
<tr>
<td>Predoctoral Student Rate</td>
<td>$60</td>
<td>$70</td>
</tr>
<tr>
<td>Honorary Member Rate</td>
<td>$0</td>
<td>$0</td>
</tr>
<tr>
<td>AACR Proceedings</td>
<td>$35 Members</td>
<td>$35 Members</td>
</tr>
<tr>
<td>Optional Overseas Surcharge</td>
<td>$45 Nonmembers</td>
<td>$45 Nonmembers</td>
</tr>
<tr>
<td>Proceedings on CD-ROM</td>
<td>$25</td>
<td>N.A.</td>
</tr>
<tr>
<td>Methods Workshop Registration</td>
<td>$35 Members</td>
<td>$35 Members</td>
</tr>
<tr>
<td></td>
<td>$45 Nonmembers</td>
<td>$45 Nonmembers</td>
</tr>
<tr>
<td></td>
<td>$50 Members</td>
<td>$50 Members</td>
</tr>
<tr>
<td></td>
<td>$75 Nonmembers</td>
<td>$75 Nonmembers</td>
</tr>
</tbody>
</table>

**TOTAL ENCLOSED OR CHARGED**  
$ ___________________  
$ ___________________

**METHOD OF PAYMENT**

☐ Check payable to AACR, Inc. in U.S. currency, drawn on a U.S. bank

<table>
<thead>
<tr>
<th>Person/Institution Issuing Check</th>
<th>Check No.</th>
<th>MasterCard ☐</th>
<th>VISA ☐</th>
<th>American Express ☐</th>
<th>Eurocard ☐</th>
</tr>
</thead>
</table>

Card Number  
Expiration Date  
Signature

An application for Associate Membership may accompany this form, but these should be submitted well before the March 1 deadline, as review of the Associate Membership application may delay registration.

*Students must enclose a statement signed by the registrar, dean, or department head of their university or college on official letterhead, confirming their status. Postdoctoral fellows or physicians in training do not qualify for the student registration rate.*

*AACR members with paid-up subscriptions to an AACR journal and registrants who pay the nonmember fee receive the *Proceedings automatically*. If these members or nonmembers check this box and pay the fee, they will receive an *additional* copy of the *Proceedings*.

*Optional payment for registrants outside of the U.S. and Canada only. Registrants paying this surcharge will receive meeting publications via airmail–printed matter before the annual meeting. This service not available after March 1.*

AACR members in good standing will receive copies of the Program and *Proceedings* prior to the meeting. Nonmember and student registrants who meet the March 1 deadline will also receive the Program and (if they have purchased it) the *Proceedings* prior to the meeting. Nonmembers and students who do not meet the deadline must pick up publications at the meeting site.

**REFUND POLICY**

Refunds on registration fees will be granted on written request received in the AACR Office by April 17, 1996. Requests received after this date will not be honored. Receipts and badges (if they have been mailed) must be returned to the AACR Office with the refund request. A cancellation fee of $35 will be deducted from all refunds to cover administrative costs.

(This form may be reproduced.)
1996 GERTRUDE ELION CANCER RESEARCH AWARD

Supported by an Educational Grant from
Glaxo Wellcome Oncology

- This Award was established in honor of Nobel Laureate Dr. Gertrude Elion, Scientist Emeritus at Glaxo Wellcome Co. and Past President and Honorary Member of the AACR.

- The Gertrude Elion Cancer Research Award is a one-year, $30,000 grant for a scientist in the U.S. or Canada engaged in meritorious basic, clinical, or translational research in cancer etiology, diagnosis, treatment, or prevention at the level of non-tenured Assistant Professor.

- The AACR will reimburse the Awardee for travel to the 1996 Annual Meeting in Washington, D.C., where Dr. Elion will personally present this Award.

Eligibility

Candidates must have completed postdoctoral studies or clinical fellowships not later than July 1 of the Award year, and ordinarily not more than five years earlier. Tenured faculty in academia, government employees, and employees of private industry are not eligible for this award. A Candidate need not be a member of the AACR at the time of application, but must be nominated by a Member of the AACR. Associate Members may not be nominators.

Selection Process

Applications are evaluated by a Committee consisting of AACR Members who are experts in basic, clinical, and translational cancer research. Complete applications must be submitted by February 15, 1996, to be considered for the 1996 Award.

For Further Information/Application Forms

AMERICAN ASSOCIATION FOR CANCER RESEARCH
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300
FAX: (215) 440-9313
e-mail: aacr@aol.com
ATTN.: Jenny Anne Horst-Martz
CALL FOR RESERVATIONS EARLY!
DEADLINE - MARCH 21, 1996

General Information

Please read this page before calling the Washington Convention and Visitors Association (WCVA) Housing Service.

Deposits

A $125.00 per room deposit is required, payable by credit card or check.

- **Credit card** - Your credit card will be charged immediately. Most major credit cards are accepted. Your room confirmation will be sent upon acceptance of your credit card charge.

- **Check** - An invoice for the $125.00 per room deposit will be mailed to you. Payment must be received within 15 days of the invoice date or your reservation will be cancelled. Do not send payment without an invoice stub. Your room confirmation will be sent upon receipt of check.

Changes

- Prior to March 21, 1996, all changes should be made with the WCVA Housing Service. After March 21, changes should be made with the hotel.

Cancellations/Refunds

- Cancellations made prior to March 21, 1996 should be made with the WCVA Housing Service and will be refunded in full. The WCVA Housing Service will issue the refund.

- Cancellations made after March 21, and prior to 72 hours of arrival should be made with the hotel. A $10.00 service fee will be deducted from your deposit. The hotel will issue the refund.

Instructions

Call the WCVA Housing Service, Monday through Friday, from 9:00 a.m. to 5:00 p.m. Eastern Time. The hotels will not accept reservations directly.

- Conferences in the United States and Canada -- call 1-800-535-3336.
- Conferences in the Washington, D.C., area and International Conferences -- call 202-842-2930.
- International Conferees ONLY -- FAX 202-289-8079.

Tell the WCVA Housing Service operator you are calling for the AACR Annual Meeting hotel reservations. Please have the following information ready:

1. Hotel preference (1st, 2nd, and 3rd choices)
2. Arrival and departure dates and times (indicate arrival after 6:00 p.m.)
3. Number of rooms required
4. Accommodations desired
   - Single
   - Double (1 bed, 2 people)
   - Twin (2 beds, 2 people)
   - Triple
   - Quad (2 double beds, 4 people)
   - Suite
5. Number of people in party
6. Credit card name, account number, name as it appears on card, and expiration date
7. Names of all occupants of room(s)
8. Address
9. Daytime telephone number with area code
10. FAX number with area code
11. Special requests (disability, smoking/nonsmoking, king-size bed, etc.)

Inquiries

Washington Convention & Visitors Association
Housing Service
1212 New York Avenue, N.W.
Washington, D.C. 20005-3992
<table>
<thead>
<tr>
<th>MAP NUMBER</th>
<th>HOTEL NAME</th>
<th>SINGLE</th>
<th>DOUBLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Grand Hyatt Washington*</td>
<td>$168</td>
<td>$188</td>
</tr>
<tr>
<td>2</td>
<td>Renaissance Washington, D.C. Hotel*</td>
<td>$154</td>
<td>$174</td>
</tr>
<tr>
<td></td>
<td>Main Hotel</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renaissance Club - Tower</td>
<td>$174</td>
<td>$194</td>
</tr>
<tr>
<td>3</td>
<td>The Bellevue Hotel</td>
<td>$109</td>
<td>$124</td>
</tr>
<tr>
<td>4</td>
<td>The Capital Hilton</td>
<td>$179</td>
<td>$199</td>
</tr>
<tr>
<td>5</td>
<td>The Comfort Inn</td>
<td>$99</td>
<td>$99</td>
</tr>
<tr>
<td>6</td>
<td>Days Inn Downtown</td>
<td>$99</td>
<td>$99</td>
</tr>
<tr>
<td>7</td>
<td>The Henley Park Hotel</td>
<td>$157</td>
<td>$177</td>
</tr>
<tr>
<td>8</td>
<td>Holiday Inn Central</td>
<td>$105</td>
<td>$105</td>
</tr>
<tr>
<td>9</td>
<td>Holiday Inn Franklin Square</td>
<td>$105</td>
<td>$105</td>
</tr>
<tr>
<td>10</td>
<td>Holiday Inn on the Hill</td>
<td>$129</td>
<td>$139</td>
</tr>
<tr>
<td>11</td>
<td>Hotel Washington</td>
<td>$150</td>
<td>$150</td>
</tr>
<tr>
<td>12</td>
<td>Marriott at Metro Center</td>
<td>$159</td>
<td>$159</td>
</tr>
<tr>
<td>13</td>
<td>Phoenix Park</td>
<td>$150</td>
<td>$170</td>
</tr>
<tr>
<td>14</td>
<td>Stouffer Renaissance Mayflower Hotel</td>
<td>$169</td>
<td>$199</td>
</tr>
<tr>
<td>15</td>
<td>The Washington Court</td>
<td>$160</td>
<td>$160</td>
</tr>
<tr>
<td>16</td>
<td>The Washington Vista</td>
<td>$155</td>
<td>$165</td>
</tr>
</tbody>
</table>

*Co-Headquarters

ALL RATES ARE SUBJECT TO A 13% DISTRICT OF COLUMBIA TAX AND A $1.50 OCCUPANCY TAX PER ROOM PER NIGHT.
MAP OF WASHINGTON, D.C. SHOWNING HOTELS SHOWING HOTELS FOR AACR REGISTRANTS

Key

A. White House
B. Union Station
C. U.S. Capitol
D. Smithsonian Institution
E. Jefferson Memorial
F. Washington Monument
G. Lincoln Memorial
H. Department of State
I. Arlington Cemetary
J. Supreme Court
K. Library of Congress

Numbers in circles correspond to hotels listed on opposite page.
CANCER CLINICAL TRIALS

The National Cancer Institute

The National Cancer Institute is seeking referral of patients with advanced cancer of the colon, stomach, esophagus, breast, lung, or bladder that is no longer responsive to standard therapy. Patients will be evaluated at the Clinical Center of the National Institutes of Health and, if found to be eligible, will be offered participation in an investigational trial of a genetically engineered immunotoxin.

For more information, please call:

(301)496-9458

AMERICAN BOARD OF INTERNAL MEDICINE

1996 Certification Examination in Hematology

Registration Period:
January 1, 1996 – April 1, 1996

Examination Date:
November 20, 1996

For more information and application forms, please contact:

Registration Section
American Board of Internal Medicine
3624 Market Street
Philadelphia, PA 19104
Telephone: (800) 441-2246 • (215) 243-1500
Fax: (215) 382-5515

AMERICAN ASSOCIATION FOR CANCER RESEARCH
1996 RESEARCH FELLOWSHIPS
For Young Scientists at the Postdoctoral or Clinical Fellow Level

The purpose of the AACR’s 1996 Research Fellowship in Clinical/Translational Research, sponsored by Amgen, Inc. and its 1996 Research Fellowship in Basic Research is to foster meritorious clinical, translational, or basic research in the U.S. or Canada by a young scientist currently at the postdoctoral or clinical research fellow level. Candidates must have been a fellow for at least two years but no more than five years prior to the beginning of the award year (July 1996). Academic faculty holding the rank of assistant professor or higher, graduate or medical students, government employees, and employees of private industry are not eligible.

Terms: Both Fellowships provide a one-year grant of $30,000. Candidates must be nominated by a member of the AACR and submit a detailed application.

Deadline: February 15, 1996

For application information contact:
Jenny Anne Horst-Martz
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
(215) 440-9300; FAX (215) 440-9313
Email: jahmaacr@aol.com

AMERICAN ASSOCIATION FOR CANCER RESEARCH

The American Association for Cancer Research (AACR) is a professional society of over 10,600 scientists and physicians involved in all aspects of basic, clinical, and translational cancer research. Members of the AACR enjoy

• subscriptions to Cancer Research, Cell Growth & Differentiation (CG&D), Cancer Epidemiology, Biomarkers & Prevention, and Clinical Cancer Research at reduced member rates
• reduced registration rates at the AACR Annual Meeting, Special Conferences, and International Meetings
• Employment Register, Directory of Members, public education activities, and many other benefits

Special programs to provide enhanced career development opportunities for minority scientists include

• Session on Career Development at Annual Meeting
• Mentorship Program
• Travel Awards to Scientific Meetings

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300
Fax: (215) 440-9313 / E-Mail: aacr@aol.com
JANUARY 17-20, 1996  
**Cancer and the Cell Cycle**  
Joint Meeting with the Swiss Institute for Experimental Cancer Research  
Chairpersons: Edward E. Harlow, Charlestown, MA; Viesturs Simanis, Lausanne, Switzerland  
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

FEBRUARY 19-25, 1996  
**Cancer Susceptibility Genes and Molecular Carcinogenesis**  
Chairpersons: Curtis C. Harris, Bethesda, MD; Allan Balmain, Glasgow, Scotland; Kenneth Olden, Research Triangle Park, NC  
Keystone Resort, Keystone, CO

MARCH 1-5, 1996  
**Proteases and Protease Inhibitors**  
Chairpersons: Lynn M. Matrisian, Nashville, TN; Bonnie F. Sloane, Detroit, MI  
Marriott's Bay Point Resort, Panama City Beach, FL

APRIL 20-24, 1996  
**87th Annual Meeting**  
Chairperson: Lorraine J. Gudas, New York, NY  
Washington D.C. Convention Center, Washington, D.C.  
*Abstract Deadline: December 1, 1995*

JUNE 8-12, 1996  
**Inducible Genomic Responses**  
Chairpersons: William T. Beck, Memphis, TN; John A. Hickman, Manchester, England; Richard I. Morimoto, Evanston, IL  
Skamania Lodge, Stevenson (Columbia River Gorge), WA

OCTOBER 2-6, 1996  
**Novel Approaches in Blood and Marrow Transplantation**  
Second Annual Meeting of the American Society for Blood and Marrow Transplantation  
Chairpersons: O. Michael Colvin, Durham, NC; Bruce R. Blazar, Minneapolis, MN  
Hotel Del Coronado, San Diego, CA

OCTOBER 6-9, 1996  
**Carcinogenesis from Environmental Pollution: Assessment of Human Risks and Strategies for Prevention**  
Joint Meeting with International Agency for Research on Cancer  
Chairpersons: Frederica Perera, New York, NY; Paul Kleihues, Lyon, France  
Hotel Gellért, Budapest, Hungary

OCTOBER 19-23, 1996  
**Programmed Cell Death**  
Chairperson: Stanley J. Korsmeyer, St. Louis, MO  
The Sagamore, Bolton Landing (Lake George), NY

JANUARY 17-21, 1997  
**Disrupted Transcription Factors in Cancer**  
Chairpersons: Peter K. Vogt, La Jolla, CA; Frank J. Rauscher III, Philadelphia, PA  
Hotel Del Coronado, San Diego, CA

FEBRUARY 13-16, 1997  
**Growth Factors and Cancer**  
Joint Meeting with Lorne Cancer Congress  
Chairpersons: Antony Burgess, Parkville, Victoria, Australia; Robert S. Coffey, Nashville, TN; Ashley R. Dunn, Parkville, Victoria, Australia; Raymond L. White, Salt Lake City, UT  
Erskine House, Lorne, Victoria, Australia

AACR members will receive brochures on the above special conferences as soon as they are available. Nonmembers should call or write:

American Association for Cancer Research  
Public Ledger Building, Suite 816  
150 South Independence Mall West  
Philadelphia, PA 19106-3483  
215-440-9300 • 215-440-9313 (FAX)  
E-Mail: aacr@aol.com
Special Plenary Session
Twenty-fifth Anniversary of the National Cancer Act: Progress and Promise (Joseph R. Bertino)

Symposia
Apoptosis: Manipulating Programmed Cell Death in Cancer (David E. Fisher)
Matrix Metalloproteinases and Their Inhibitors (Lynn M. Matrisian)
Cell Cycle: Targets for Therapy (Stephen H. Friend)
Endogenous DNA Damage: Detection and Biological Significance (John M. Essigmann)
Cell Signaling (Channing Der and Deborah Morrison)
Recent Developments in Gene Therapy (Drew M. Pardoll)
Cancer Chemoprevention in Humans (Thomas W. Kensler)
Genetic Predisposition to Cancer (Mark H. Skolnick)
Cell Responses to DNA Damaging Agents (Nathan A. Berger)
Drug Resistance: Transcriptional and Translational Mechanisms (Kwame W. Scott)
Monoclonal Antibodies: Clinical Mechanisms and Effectiveness (Ellen S. Vitetta)
Targeting Growth Factor Receptors for Therapy (John Mendelsohn)
Melanoma as a Clinical Model (Alan N. Houghton)
Thymidylate Synthetase and Its Inhibitors
Nourishment and Cancer (Walter C. Willett)
Aberrant Transcription Factors and Malignancy (Lorraine J. Gudas)
Steroid Hormones: Breast and Prostate Cancer (Myles A. Brown)
Viral Mechanisms of Carcinogenesis (Harald zur Hausen)
Tumor Suppressor Genes (Bert Vogelstein)
Ovarian Cancer: From the Laboratory to the Clinic (Robert F. Ozols)
Drug Metabolizing Enzymes in Cancer Prevention and Therapy (Cecil B. Pickett)
Cell Adhesion Molecules and the Cytoskeleton (Jun-Lin Guan and Rudolph L. Juliano)
Tumor Angiogenesis (Judah Folkman and Mark A. Goldberg)
Neuroblastoma: Recent Advances in Diagnosis and Treatment (Garrett M. Brodeur)
Telomerase, Cell Senescence, and Cancer (Calvin B. Harley)

Pre-Meeting Methods Workshops
Quantitative Biology and Pharmacodynamics (Robert C. Jackson)
Animal Models: Transgenic and Knockout Mice in Cancer Investigations (Terry A. Van Dyke)

Controversy Sessions
Does Regional Chemotherapy Work? (David S. Alberts)
Is Beta-Carotene Useful in Cancer Prevention? (Waun Ki Hong)
In Studies of Drug Resistance, Have Preclinical Models Provided Accurate Predictions for Clinicians? (Bruce A. Chabner)
Is p53/Rb Important for Therapeutic Outcome? (William F. Benedict)
Should Genetic Testing Be Done on Patients to Assess Cancer Risk? (Judy E. Garber)

Meet-The-Expert Sunrise Sessions
Quantitative PCR As a Tool to Detect Minimal Residual Disease in Lymphoma and Leukemia (John Gribben)
Inhibition of Tobacco-induced Carcinogenesis (Stephen S. Hecht)
Cell Cycle (Peggy J. Farnham)
Drugs Which Interact with Microtubules: An Update (Eric K. Rowinsky)
Culturing Normal and Neoplastically Transformed Human Epithelial Cells (Martha R. Stampfer)
Mammary Carcinogenesis (Daniel Medina)
Radiation Sensitization (Theodore S. Lawrence)
NMR As a Prognosticant (Jerry D. Gluckson)
Antiestrogens (V. Craig Jordan)
DNA Topoisomerases and Their Inhibitors (Yves G. Pommier)
Estrogens and Breast Cancer (Lovell A. Jones)
Tumor Physiology (Rakesh K. Jain)
Protein Kinase C in Cell Transformation (Susan Jaken)
Environmental Carcinogens: Their Impact in Cancer (John A. McLaughlin)
Lung Cancer: A Primer (Robert J. Enyedi)
Chromosomal Deletions and Cancer: Recent Advances in Mapping Techniques (Funmi I. Olopade)
Tumor Vaccines (Jeffrey Schlim)
Challenges in Bone Marrow Transplantation (William S. Dalto)
Immunologic Features of AIDS Pathogenesis (Jay A. Levy)
Natural Killer Cells (Ronald B. Herberman)
Interferons and Cancer (Ernest C. Borden)
Transcription Factors As Therapeutic Targets (Richard A. Heyman)
Chemokines and Leukocyte-specific Chemotactic and Activating Factors (Barrett J. Rollins)
Bcl and Cell Death (Stanley J. Korsmeyer)
Prodrugs (Peter D. Senter)
Specific Immunotherapy of Melanoma (Philip Livingston)
Diet and Tumorigenesis (Diane F. Birt)
Childhood Leukemias: The Latest in Treatment (Steven E. Sallan)

April 20-24, 1996
Washington, D.C.
Convention Center

The Latest Developments in All Areas of Cancer Research
Program Chairperson: Lorraine J. Gudas

Major Presentations of the Foremost Scientists in the Field
Abstract Deadline: December 1, 1995

Minisymposia, Poster Discussion Sessions, and Poster Sessions Proffered Papers

For More Information: AACR Office
Public Ledger Building
Suite 816
150 S. Independence Mall
Philadelphia, PA 19106-3494
215-440-9100
Fax 215-440-9131
Email aacr@aol.com

An Essential Multidisciplinary Program for Laboratory and Clinical Cancer Researchers